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1. Noninvasive imaging of angiogenesis could provide clinicians a new to in det�r�ination of 
individuals with higher risk for cardiovascular events. 
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"Too well off, that's why I left;' Santiago says. "I was so pure and thick-headed that it bothered 
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myself a real little man, Ambrosio" 
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Adapted from: 
Small-animal SPECTand SPECT/CT: application in cardiovascular 
research. Eur J Nuc/ Med & Mo/ Imaging. 2010;37:1766-77 
Adverse cardiovascular effects of anabolic steroids: pathophysiology 
imaging. Eur J Clin Invest. 2012;42(7):795-803 
Abstract 
Preclinical cardiovascular research using non-invasive nuclear medicine hybrid 
imaging systems has been extensively developed in recent years. Positron 
emission tomography (PET) and single photon emission computed tomography 
(SPECT) are based on the molecular tracer principle and is an established tool in 
non-invasive imaging. PET imaging system utilizes gamma cameras to detect two 
back to back gamma rays which are emitted after positron annihilation. SPECT uses 
gamma cameras and collimators to form projection data that are used to estimate 
(dynamic) 3-D tracer distributions in vivo. Recent developments in multipinhole 
collimation and advanced image reconstruction have led to sub-millimeter 
and sub-half-millimeter resolution SPECT in rats and mice, respectively. In this 
article we review applications of microSPECT with and without combined with 
microCT in cardiovascular research in which information about the function and 
pathology of the myocardium, vessels and neurons is obtained. Some potential 
applications of (micro)PET in investigating pathobiological processes involved in 
atherosclerotic plaque are suggested. And we give examples on how diagnostic 
tracers, new therapeutic interventions, pre- and post-cardiovascular event 
prognosis, and functional and pathophysiological cardiovascular conditions can 
be explored by microSPECT(CT) and microPET(CT), using small-animal models of 
cardiovascular disease. 
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Nuclear medicine techniques 
Nuclear Medicine currently plays a key role in diagnosis of patients in various 
areas of clinical medicine including: neurology, oncology, orthopedics, urology, 
pulmonology, and cardiology. Nuclear imaging can provide information at 
molecular, cellular, organ, and whole body level to evaluate perfusion, metabolism, 
function and as such can facilitate prognosis, and assess response to therapy. The 
advantage of non-invasive detection of physiological changes in vivo established 
the role of positron emission tomography (PET) and single photon emission 
computed tomography (SPECT) as two major nuclear imaging modalities for 
evaluation of a wide range of clinical conditions including: myocardial perfusion, 
myocardial metabolism, evaluation of post-infarction myocardium, staging of 
tumors, detection of metastases, diagnosis of osteomyelitis, etc. 
Furthermore, better understanding on pathophysiology of diseases, thanks to 
progresses in proteomics and genomics, provides opportunities to extend the 
level of evaluation of a living system from physiology assessment to quantification 
of molecular/cellular biomarkers underlying diseases. Molecular imaging would 
benefit individuals and clinicians with a better understanding of diseases and 
offer the chance for an individual-based therapeutic intervention. Molecular 
imaging research is a multidisciplinary approach which comprises expertise in 
biology, pharmacology, chemistry, physics, and medicine. 
Development and application of nuclear medicine techniques in molecular 
imaging has to address three important questions. 
1. An appropriate molecular or cellular target which is relevant to the disease of 
interest should be identified. 
2. Second, an appropriate ligand which has specific affinity to target and contains 
a detectable label should be developed. In nuclear medicine imaging; single 
photon emitter (e.g. [99mTc], [111 In], [201TI]) or positron emitting radioisotopes 
[e.g. [18F], [11 CJ, [1 SO]) are incorporated into molecules or added onto ligands 
to form radiopharmaceuticals. 
3. An appropriate imaging system should be applied to detect the tracer. In 
nuclear medicine PET imaging system is used to detect positron emitting 
radiopharmaceuticals and is based on detection of two back to back gamma 
rays emitted as a result of positron annihilation whereas; SPECT imaging 
system is used to detect photons using photon (gamma ray) sensitive radiation 
detectors. 
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Small-animal imaging of cardiovascular disease 
Small-animal models of cardiac disease play an important role in cardiovascular 
research, and the ability to translate the findings to the clinic has been proven in 
many cases [1-3]. The use of radionuclide imaging in small animals has provided 
many advantages for researchers to investigate in vivo molecular processes 
in cardiovascular pathology. Small-animal SPECT systems are now used by 
many centers for tracer development, therapy evaluation and pathophysiology 
investigations. Here we discuss the basic principles and preclinical applications of 
microSPECT and combined microSPECT/CT in cardiovascular research. In addition, 
a brief review on potential application of micro positron emission tomography 
(microPET) in the context of atherosclerotic disease will be provided. 
Background of microSPECT(CT) and microPET(CT) 
MicroSPECT(CT) 
SPECT is based on the molecular tracer principle and detection of gamma rays 
by radiolabelled molecules. The suitable energy range of gamma rays for clinical 
SPECT is typically around 60-300 keV. Due to the small size of rats and mice, 
isotopes with much lower energies (e.g. 1251, with 27-35 keV) could be employed 
in microSPECT, but is not feasible to image patients. For obtaining tomographic 
images, tens up to hundreds of projection images of the animal are acquired 
with position-sensitive gamma-detectors. Today almost all small-animal SPECT 
is performed with pinhole collimators, since these collimators provide a much 
better noise resolution trade-off in small objects than parallel hole or fan-beam 
collimators that are commonly used in clinical cardiac SPECT. Most small-animal 
SPECT systems rotate either the detector and collimator or the object [4-12]. 
Stationary small-animal pinhole SPECT systems [13-17] do not need to be rotated 
since they use detector set-ups that cover 360° and many pinholes to provide a 
large number of projection angles under which the animal is observed. They also 
have the advantage that dynamic imaging is possible with arbitrarily short frame 
lengths [15, 18, 19]. 
The full 360° coverage in combination with many focusing micropinholes and a 
high magnification factor to maximize the information content per photon provide 
a very high reconstructed image resolution. Multiple projections from different 
angles that can be acquired at the same time in such systems facilitate excellent 
ECG-gated myocardial imaging in rats and mice, which have heart rates of around 
300 and 600 beats per minute, respectively. For instance, the U-SPECT-11 system 
(Mllabs, The Netherlands) has 75 pinholes on its interchangeable cylindrical 
collimators (Figure 1 ), and is based on three ultra-large Nal scintillation gamma­
cameras. Reconstructed images can reach resolutions of :50.35 mm and 0.45 mm 
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anywhere in the body using the mouse collimators with 0.35 mm and 0.6 mm gold 
pinhole apertures, respectively, and �0.8 mm with the standard total body rat 
collimator. It is expected that dedicated high-resolution detectors will contribute 
to further improvement in multi-pinhole SPECT resolution, thereby expanding 
the field of application of microSPECT. In addition, dedicated collimators to 
image specific organs are under development, and these can dramatically boost 
performance. Overviews and primers of pinhole SPECT technology have been 
provided by some investigators [20, 21]. 
a 
b 
Figure 1. a) Separate U-CT system and U-SPECT-11 system. 
b) Integrated U-SPECT-11/CT system. 
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In contrast to PET, dual-tracer or triple-tracer images can be readily obtained 
with SPECT. Multi-tracer imaging results in shorter acquisition times and perfect 
registration of images in space and time, and each tracer represents a different 
biological process. Another advantage of SPECT is that radiotracers can be 
produced more easily in the laboratory without the need for a cyclotron, so that 
the cost-effectiveness of SPECT is higher than that of PET. Clinical PET systems 
have a much higher resolution than SPECT, but this is reversed for microSPECT 
since the best resolution of commercial microPET systems is still above 1 mm [22, 
23]. 
Perfusion SPECT provides valuable information for the diagnosis of patients with 
coronary artery disease (CAD). For example, in triple vessel disease, in which tracer 
delivery to the whole myocardium is diminished due to balanced hypoperfusion, 
SPECT images may be interpreted as normal in qualitative or semi-quantitative 
image analysis because comparison of the defective area with the region of 
the most intense uptake will not show any difference from normal. Absolute 
quantification of tracer uptake, which measures megabecquerels of tracer uptake 
per gram of tissue, can solve this problem [24]. The most prominent obstacles 
to absolute quantification in clinical SPECT used to be photon absorption and 
scattering, but today these problems are much smaller: SPECT systems equipped 
with transmission sources or, more recently, integrated with CT scanners are on 
the market [25-28]. These allow accurate correction for attenuation, and also 
use accurate methods to correct for scatter and collimator and detector blurring 
[29-38]. Cardiac and respiratory movements also degrade quantification, but 
both could be dealt with through (dual) gating as used in microPET imaging 
[39]. Although significant technical improvements for absolute quantification of 
myocardial perfusion using microSPECT have been introduced in recent years, the 
"roll-off" phenomenon with typical commercial SPECT perfusion agents under 
hyperemic conditions, even in humans with less myocardial blood flow than 
mice, still remains a limitation for accurate measurement in myocardial perfusion 
imaging. 
Quantification errors due to scatter and attenuation do degrade small-animal 
studies to a much lesser extent than in clinical SPECT because of less photon 
attenuation in small bodies (about 25% in the centre of a rat body when imaging 
with [99mTc] [40]). MicroCT imaging is able to provide photon attenuation 
information which can be used for non-uniform attenuation correction in 
microSPECT. However, several studies [40, 41] have shown that uniform 
attenuation correction (which may be based on the animal's body contour) may 
reduce quantification errors from more than 10% to less than 5%. Therefore, a 
CT scan that adds dose and needs additional scanning equipment and scan time 
may be unnecessary. A webcam-based correction has been proposed [41 ]. 
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The accuracy of registration can be very satisfactory (0.2 mm), and an advantage 
is that SPECT and CT can be used in parallel, and are individually upgradable. Also 
registration with other systems such as MRI can be based on the same principles. 
The advantage and disadvantages of both approaches have been discussed [34, 
45]. 
Figure 2. U-SPECT gated mouse cardiac perfusion images obtained in a normal C57BU6 mouse 
ED = end diastole; ES = end systole) 
An attractive aspect of high-resolution integrated microSPECT/CT devices 
[46-49] (e.g. Figure 1 b) is that the bed with the fixed animal does not have to 
be moved from one scanner to another. Integrated SPECT/CT, in which the bed 
moves through both the SPECT and the CT scanner is very convenient, although 
this approach is hard to extend to MRI, and image registration is still needed to 
obtain accurately matched combined images. 
The translatability of the cardiovascular systems of small animals including mice 
and rats to the human cardiovascular system and the exceptional characteristics of 
modern microSPECT and multimodality imaging approaches provide promising 
opportunities in preclinical cardiovascular research. Novel microSPECT systems 
can provide quantitative images, and can perform longitudinal studies in the same 
animal, a high pinhole magnification factor resulting in high resolution, possibly 
dynamic imaging, and multitracer imaging. MicroSPECT and microSPECT/CT 
systems have a wide range of applications in preclinical cardiovascular research, 
including investigation of myocardial left ventricular (LV) parameters such as 
ejection fractions and volumes, cardiac innervation parameters, vascular and 
atherosclerosis parameters, and the timing of administration and dose of novel 
radiotracers and biomarkers. 
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MicroPET(CT) 
MicroPET is, like microSPECT, is based on the external detection of radiolabelled 
tracer with gamma cameras. The important difference between PET and SPECT 
is the use of positron emitters as radiolabels. Positron annihilation results in 
emission of two back to back gamma rays, coincidental detection of which 
defines line of sight of positron annihilation. As such, (micro)PET systems do not 
require collimation and therefore offer a better molar sensitivity and possibility 
of absolute quantification. Moreover, labeling characteristics of positron emitters 
are better suitable for producing radiopharmaceuticals. 
Although microPET imaging offers many advantages over microSPECT, its major 
drawbacks are requirement for on-site cyclotron for isotope production and 
expensive technology and radiochemistry lab setup. 
Myocardial applications 
Left ventricular function 
In order to assess the functional condition of the heart in transgenic mouse 
models in vivo, small-animal heart imaging can be used for verifying phenotypic 
differences as well as assessing the benefits of certain therapies. The ability to 
acquire gated images in small rodents which have high heart rates has eliminated 
the heart motion effect (Figure 2). It has been shown that [99mTc]-labeled 
radiopharmaceuticals, which are routinely used for SPECT imaging in humans, 
can demonstrate viable tissue and perfusion status in animal models of ischemia/ 
reperfusion [14]. Further studies have demonstrated that myocardial perfusion 
defects are correlated with the true size of the defect, and can be analyzed 
quantitatively as well as qualitatively [50, 51 ]. Liu et al. used animal models of 
myocardial ischemia with coronary artery ligation and acquired images after 
[99mTc]-sestamibi injection. 
The area where no uptake was seen corresponded with the infarcted tissue which 
was confirmed by triphenyl tetrazolium chloride (TTC) [14]. 
Cardiac and respiratory motion can always affect image resolution in SPECT 
and CT. In order to overcome this problem gating (cardiac and/or respiratory) is 
performed to synchronize the acquisition of projected data at the same time of the 
cardiac cycle. Gating also offers the chance to simultaneously map LV perfusion 
and assess LV function in clinical SPECT applications. ECG-gated microSPECT has 
been implemented in recent years. It has been shown that preclinical ECG-gated 
perfusion SPECT (in mice) permits quantification of LV volumes and motion as 
well. This is also a result of advances in image reconstruction software [52, 53]. 
The non-invasive nature of the test allows repeated studies in the same animal for 
follow-up studies [54]. 
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Necrosis visualization 
The development of necrotic tissue-avid tracers may help early detection of 
myocardial infarction (Ml) non-invasively. In vivo visualization of necrotic tissue 
may also provide a quantitative index for evaluating the anti-necrotic effect of 
drugs in development in animal models of ischemic heart disease. 
Glucarate is a small molecular weight compound, a six-carbon dicarboxylic acid 
sugar, which has affinity for histone proteins. In necrotic cells, due to lesions in the 
cellular and nuclear membranes, [99mTc]-glucarate can bind to histone proteins 
and be retained in the tissue [55]. 
It has been shown that only minimal levels of glucarate bind to normal myocardial 
cells and viable ischemic cells. Further studies have illustrated the possibility of 
immediate post-injection imaging with [99mTc]-glucarate due to its rapid blood 
clearance [56]. Thus, by using [99mTc]-glucarate as a SPECT tracer, necrotic cells 
can be depicted to provide data in acute coronary syndrome. Additionally, 
imaging of infarcts is possible within minutes of occlusion [57-59]. Moreover, it 
has been shown, by comparative investigations using TTC staining, that SPECT 
images of [99mTc]-glucarate uptake allow accurate assessment of infarct size. 
Conversely, it has been shown that there is no glucarate uptake in old necrotic 
myocardial tissue. Although glucarate uptake in necrotic tissue occurs as early as 
3 hours after ischemia/reperfusion, at 1 0  days after necrosis there is no obvious 
tracer uptake in the heart [60]. 
Some studies have focused on other necrotic tissue-avid tracers than glucarate 
compounds. Porphyrin derivatives were initially developed as tracers for tumor 
cell tracking. Reports of the avidity of porphyrin derivatives for necrotic tissue 
[61-63] and studies on their use in visualization of infarcted tissue by MRI led to 
efforts to radiolabel hypericin. Hypericin is a natural substance with a biological 
activity similar to that of porphyrin. 
Both substances are known to be photosensitizers and have been used in anti­
tumor therapies [64]. Ni et al. synthesized mono-[123I]iodohypericin (MIH) and 
injected it into rabbit models of Ml. SPECT imaging compared to TTC staining and 
autoradiography confirmed the accumulation of [ 1 23I]-MIH in the infarcted tissue 
[65]. In addition, due to the minimal levels of tracer uptake in normal myocardium, 
the target to non-target tracer concentration ratio was very high. In another study, 
Fonge et al. compared the results of [1231]-MIH microSPECT with the results of 
[13N]ammonia microPET in rabbit models of Ml. There was a correlation between 
areas with low blood flow in microPET and [123I]-MIH uptake in microSPECT [66]. 
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Apoptosis visualization 
Apoptotic cell death has been the subject of many studies investigating 
opportunities for therapeutic interventions. Apoptosis is an energy-requiring 
highly regulated form of cell death which is characterized by cell shrinkage, DNA 
fragmentation, caspase activation, membrane blebbing, and phosphatidyl serine 
(PS) externalization. It has been demonstrated that reperfusion injury in the heart 
leads to apoptotic cell death [67-70]. The role of apoptotic cell death in heart 
failure has also been investigated in many studies [71-73]. The development 
of radiopharmaceuticals that bind to apoptotic cells has been useful for in vivo 
evaluation of therapeutic efforts in apoptoticcell death in cardiomyocytes. Annexin 
AS, a 36-kDa physiological protein, has affinity for binding to the externalized PS. 
[99mTc]-Annexin AS has been used as a SPECT tracer in recent years for detecting 
apoptosis in the preclinical and clinical settings in vivo. [99mTc]-Annexin AS uptake 
has been confirmed by apoptosis-specific immunohistochemistry assays [74-80]. 
Nevertheless, PS exposure has been shown not to be specific for apoptotic cell 
death. In necrosis as well, due to leakage in the cell membrane, PS can be exposed 
and bound to Annexin AS. Annexin AS can visualize apoptotic PS externalization 
specifically, if used with a second marker showing an intact cell membrane [81 ]. 
More recently, a new [99mTc]-bound, PS-avid agent has been developed. The C2A 
domain of synaptotagmin, which binds to PS in a calcium-dependent manner, 
has been shown to be sensitive for cell death detection [82]. False-positive 
uptake, due to some extent to PS exposure in other forms of cell death, led 
investigations to find more specific tracers for apoptosis visualization. Caspase-3, 
altered membrane permeability, and several enzymes which are responsible for 
apoptosis, are appropriate potential novel targets for apoptosis imaging. 
Stem cell therapy evaluation 
The recent treatment strategy for cell-death-related heart disease, cellular 
cardiomyoplasty, needs to be evaluated in preclinical investigations. The most 
important objectives for the investigations are the optimal cell type, route of 
delivery, number of cells, suitable timing after infarction, and future monitoring of 
grafted cells. Imaging modalities may help stem cell therapy in the heart in three 
ways, including tracking and quantification of transplanted cells, assessment of 
function and differentiation, and monitoring of underlying tissue status, as well 
as in assessing the problems involved in the generation of suitable cell materials 
[83-85]. Zhou et al. used stem cell grafts labeled with [111 ln]-oxyquinoline and 
performed double tracer ultrahigh resolution SPECT with [99mTc]-sestamibi to 
evaluate the engraftment of the stem cells in the infarcted area [86]. However, due 
to the half-life of [111 ln]-oxyquinoline (67.2 h) the imaging could be only done 
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within 96 h of engraftment, and because radioactivity in stem cells remains in the 
area even after the cells have died, quantification of uptake may overestimate the 
survival fraction of injected stem cells. Thus, this method may be useful for short­
term tracking of the cells and investigating homing strategies for engraftment. 
To assess the function of the targeted cells by SPECT, gene imaging can also be 
used. Gene expression can be assessed by reporter genes. For imaging with a 
reporter system, a probe is administered to the subject and selectively bound 
or metabolized with the reported gene product. This interaction results in probe 
trapping by the transgenic cell and its level is proportional to the gene expression. 
The result shows the functionality of the cell. One of the reporter genes most used 
in this regard is herpes simplex virus tyrosine kinase (HSV1 -tk), which is absent 
in mammalian cells and expresses the tyrosine kinase enzyme that converts 
cytosine to uracil. Hence, only transgenic cells which express this gene can convert 
5-fluorocytosine to 5-fluorouracil, and administration of radiolabeled nucleoside 
to the subject and acquisition with SPECT will show the tracer uptake in the area 
of cells expressing the reporter gene [87]. 
A study on tumor cells has shown the sensitivity of the d-isomer of [123I]-2'-fluoro-
2'-deoxy-1-beta-d-arabino-furanosy-5-iodo-uracil (d-FIAU) in detecting cells 
positive for HSV1-tk [77]. It has been shown in a study on Wistar rats injected with 
the adenovirus-expressing hNIS gene that imaging with iodine and technetium 
tracers can verify the activity of cardiomyocytes [88]. Thus, transferring the gene to 
the stem cells prior to myocardial cell transplantation can aid the further tracking 
and monitoring of the graft. Furthermore, for assessment of gene therapy, co­
expression of the hNIS gene with the gene of choice has shown promise for 
future monitoring of cardiac gene therapy. However, one potential obstacle in 
the use of hNIS for stem cell tracking is gene silencing, which has been reported 
in neurological studies [85]. 
Remodeling investigations 
LVremodeling after Ml leads to LV dysfunction and failure. Matrix metalloproteinase 
(MMP), a proteolytic enzyme, has been shown to play a causal role in this process 
[89]. In vivo MMP activation imaging may provide data to quantify and localize 
MMP activity and its role in further LV remodeling. In addition, MMP imaging 
provides the opportunity to track therapeutic efforts directed at MMP inhibition to 
reduce post-Ml remodeling. Su et al. investigated the activation of MMP enzymes 
with microSPECT/CT in mice models of Ml. They used a [99mTc]-bound radiotracer 
(RP805) to visualize MMP in vivo and compared it to in situ zymography, and 
found a good correlation between the results [90]. 
The role of blood coagulation factor XIII in post-Ml healing has also been studied 
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using [11 1 ln]-NQEQVSPLTLLK [77]. The non-invasive imaging of factor X III may 
help further investigations on the assessment of factor XIII-targeted therapies 
[91 ]. 
Innovative pathophysiology investigations 
A better understanding of pathophysiology can shed light on the pathological 
processes in cardiovascular diseases, and may lead to new therapeutic 
interventions. Animal models, especially mice and rats, have been used 
traditionally for the investigation of molecular processes in cardiovascular 
diseases. Radionuclide imaging has significantly improved our understanding 
of several aspects of pathophysiology in small animal models. For instance the 
role of sigma receptors in cardiomyocytes has been studied in recent years. 
Their role in blocking the potassium channel and decreasing neuroexcitability 
in intra-cardiac neurons has been reported by Zhang and Cuevas [92]. Sigma 
receptors are a largely unexplored area of cardiology, and should be studied. 
Recent efforts towards radionuclide imaging of sigma receptors in various organs 
can be expanded in cardiology to better distinguish sigma receptor function in 
cardiovascular systems [93]. 
In another investigation, [99mTc]-losartan was used for non-invasive imaging of 
angiotensin receptors in mouse heart muscle cells after permanent ligation of 
the left anterior descending artery [94]. Increased tracer uptake in post-Ml hearts 
and its correlation with remodeling showed the role of the renin-angiotensin axis 
in progression of heart failure after Ml. In addition, this study demonstrated the 
potential role of non-invasive imaging strategies in identification of patients likely 
to develop heart failure. 
Cardiac innervation imaging 
The autonomic nervous system plays an important role in cardiovascular diseases. 
Disturbances in function and integrity, as well as enhanced sympathetic activity 
may lead to numerous heart pathologies. Therefore, evaluation of the sympathetic 
innervation of the heart could provide important data on the etiology and 
progress of heart diseases. 
It might also provide a tool for non-invasive assessment of novel therapeutic 
approaches targeting sympathetic nervous system activity, and also assessment 
of the side effects of drugs on cardiac adrenergic function. 
1 23I-labelled metaiodobenzylguanidine ([1 23I]-MIBG), an analogue of the false 
neurotransmitter guanethidine, has been used clinically for sympathetic neuronal 
activity and integrity since the 1 980s. Pre-synaptic sympathetic nerve terminals 
can take up and store MIBG in the same way as norepinephrine. Thus, MIBG 
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uptake and washout rate can be influenced by sympathetic tone and the integrity 
of nerve terminals. Studies using [123I]-MIBG in animal models of coronary artery 
occlusion have revealed more extended nerve damage than myocardial injury 
in Ml [95]. Also, some investigations have focused on the role of denervation 
in diabetic heart disease and cardiomyopathy [96]. [123I]-MIBG uptake defects 
have also been shown to be related to arrhythmogenesis in the heart after CAD, 
cardiomyopathy and other cardiac pathologies [97]. Due to more favorable 
properties of [99mTc]-bound radiopharmaceuticals compared with [123I]-based 
tracers, Samnick et al. labeled 1-(4-fluorobenzyl)-4-(2-mercapto-2-methyl-
4-azapentyl)-4-(2-mercapto-2-methylpropylamino)-piperidine (FBPBAT)  with 
[99mTc] and compared its characteristics in the assessment of cardiac adrenergic 
function in the rat with those of [123I]-MIBG [98]. They used rat models pretreated 
with al  and 131 inhibitors and acquired SPECT images after radiopharmaceutical 
incubation. [99mTc]-FBPBAT showed higher uptake than [123I]-MIBG. [99mTc]­
FBPBAT also had more cardiac adrenergic specificity. Moreover, [99mTc]-FBPBAT 
targeted postsynaptic adrenoreceptors, whereas [123I]-MIBG was absorbed via 
a presynaptic uptake I route. In another study, the average effective dose of 
[99mTc]-FBPBAT was shown to be less than half that of [123I]-MIBG [99]. These 
studies encourage further investigations of [99mTc]-based radiopharmaceuticals 
for SPECT studies of cardiac adrenergic innervation [97]. 
Vascular applications 
Plaque imaging 
Rupture of atherosclerotic plaque results in severe cardiac events in 70% of 
acute Mis and sudden cardiac death. Anatomical methods of atherosclerosis 
imaging visualize coronary artery stenosis, which is responsible for 20% of 
plaque complications. However, the majority of acute coronary events are 
a consequence of rupture and further thrombotic occlusion in non-stenotic 
lesions. Criteria to regard a plaque as rupture-prone and vulnerable have been 
suggested by Naghavi et al, [100]. The important attributes regarding injury, 
inflammation, thrombogenicity, proteolysis, stenosis and morphology play a role 
in the prediction of plaque vulnerability. The major criteria for labeling a plaque 
as vulnerable include: active inflammation (monocyte/macrophage and T-cell 
infiltration), thin cap with large lipid core, superficial platelet aggregation, fissure, 
and stenosis >90%. Apart from CT-provided data on stenosis, molecular imaging 
techniques have been widely used in recent years to depict biological processes 
within plaque regarding other plaque vulnerability criteria as mentioned above 
[101 ]. It is particularly noteworthy that the characteristics of the most common 
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type of vulnerable plaque are inflammatory cell infiltration, platelet aggregation, 
MMP activation, large lipid core content and apoptosis, but not significant 
stenosis [102]. Thus, addition of molecular imaging techniques to routine plaque 
assessment procedures can potentially provide better recognition of vulnerable 
atherosclerotic plaques. 
Apoptosis in plaques 
Apoptosis is one of the characteristics of a vulnerable atherosclerotic lesion. It has 
been shown that apoptosis occurs in smooth muscle cells and monocytes in the 
plaque, and is a good target for visualizing atherosclerotic plaque, in addition to 
categorizing plaques as vulnerable. In a study on the detection of atheroma in the 
aorta of balloon-injured rabbits, focal [99mTc]-Annexin AS uptake was shown to 
be correlated with macrophage apoptosis in the plaque [102]. 
lsobe et al. demonstrated that SPECT/CT imaging with Annexin AS compounds 
provides appropriate correlation between tracer uptake and apoptosis in plaques 
[103]. They showed that in ApoE-/- mice, induced atherosclerotic plaque can be 
detected by [99mTc]-Annexin AS, and the quantitative uptake is related to the 
macrophage content of the plaque. Reduced [99mTc]-Annexin AS uptake after 
diet modification and simvastatin therapy has been shown in another study [ 1 04]. 
Thrombogenicity 
Thrombosis at the rupture site or the sites of superficial erosions on the plaque is 
another marker that predicts the vulnerability of plaque. Thrombosis visualization 
can help predict future events in CAD. Fibrin detection by CT using fibrin-targeted 
nanoparticles has recently been reported in humans [105]. It can also be used in 
animal models of cardiovascular diseases to evaluate therapeutic interventions 
for thrombosis formation and dissolution. 
Lipoprotein accumulation 
Vulnerable plaques contain more than 40% low-density lipoproteins in their 
core [100]. [99mTc]-labeled oxidized low-density lipoproteins (oxLDL) allow 
visualization of lipid accumulation within macrophages and foam cells. Iuliano et 
al. showed rapid blood clearance and tracer uptake by atherosclerotic plaque in 
humans [ 1 06]. Further studies quantifying tracer uptake and its contribution to 




The inflammatory nature of atherosclerosis, due to infiltration of the plaque with 
macrophages/monocytes and T lymphocytes, provides a target for cell content 
imaging of atherosclerotic plaques. lnterleukin-2 (IL-2), labeled with [99mTc], 
was used by Annovazzi et al. to demonstrate T-cell infiltration in human carotid 
artery atherosclerotic plaques [1 09]. This study showed the accumulation of 
tracer in vulnerable plaques and also demonstrated the consequent influence 
of lipid-lowering on uptake. Circulating monocyte recruitment in the plaque site 
and lipid phagocytosis by phagocytes have also been studied as approaches 
to inflammation visualization in atherosclerotic plaques. Although most 
investigations in this field have been done using microPET, the known advantages 
of SPECT systems and SPECT specific tracer labeling should stimulate more studies 
on plaque inflammation by microSPECT. 
[ 1 8F]-fluorodeoxyglucose ([1 8F]-FDG) PET has been studied in a notable number 
of investigations, and has been shown to correlate with the macrophage density in 
atherosclerotic plaques in humans and in animal models [ 1 1 O]. Additionally, [ 1 8F]­
FDG PET depicts myocardial infarction subsequent to coronary atherosclerosis. 
Figure 3 shows a whole body cardiac gated [ 1 8F]-FDG PET/CT image of a male 
bodybuilder with abdominal aortic calcification (Figure 3a) with more extensive 
FOG uptake in aortic plaques (Figure 3b) and an inferolateral myocardial infarction 
(Figure 3c) as a result of right coronary artery occlusion. 
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Figure 3. 1 BF-FOG PET/CT image of androgenic-anabolic steroid-associated atheroscerosis. Whole 
body 1 BF-FDG PET/CT of a 40-year-old male body builder with mild abdominal aortic atherosclerosis 
on CT (a, arrow) and more extensive FOG uptake in soft plaques of abdominal/iliacal arterial tract on 
PET (b, arrow) and (c) gated myocardial 1 BF-FOG PET in the same patient indicating an inferolateral 
infarction (arrow) owing to acute right coronary artery occlusion. 
FOG = fluorodeoxyglucose; PET=  positron emission tomography. 
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Proteolysis 
Activation of MMP in the atherosclerotic plaque may lead to further instability 
and rupture. Schafer et al. studied the feasibility of using a 1 23!-labelled MMP 
inhibitor in a known model of arterial remodeling and lesion development 
[ 1 1 1  ]. They showed that SPECT imaging using [ 1 23I]I-HO-CGS 27023A can be 
an appropriate method for measurement of MMP activity within the plaque. In 
another study, a [99mTc]-labeled broad MMP inhibitor was used to determine 
the effects of statin therapy and dietary modification on MMP activation in rabbit 
models of atherosclerosis [ 1 1 2]. The microSPECT/CT results were compared 
with histological and immunohistochemical results as well as the results of ex 
vivo autoradiography, and showed the feasibility of non-invasive MMP activity 
detection (Figure 4). 
Angiogenesis in plaque 
Angiogenesis in atherosclerotic plaque may cause intra-plaque hemorrhage and 
therefore contribute to more risk of plaque rupture. It also plays an important 
role in infarct healing and post-Ml LV remodeling. Imaging of angiogenesis with 
specific tracers which are avid to angiogenic factors, by SPECT or PET, can also 
reveal valuable information on plaque. Imaging of intra-plaque hemorrhage, if 
possible, will also provide valuable information on plaque vulnerability. Davies 
et al. showed that a proportion of Annexin V uptake in atherosclerotic plaque is 
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Figure 4. Uptake of RPBOS (a broad-spectrum MMP ligand) demonstrating MMP expresion in an 
atherosclerotic rabbit on an uninterrupted diet. The three columns display transverse, sagittal, and 
frontal projections, and the three rows display microCT, microSPECT, and fusion images. The left set of 
three columns displays images immediately (o h) after radiotracer administration (representing blood 
pool images), and the right set of three columns displays images obtained at 4 h (representing tracer 
uptake in target tissue). The images were adapted from [1 12] 
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Thus, non-invasive imaging of angiogenesis may improve risk stratification in 
post-Ml patients. Angiogenesis imaging can also provide a tool to evaluate 
therapeutic interventions aimed at angiogenesis stimulation. lntegrins, a family of 
cell surface receptors, are known to play a role in angiogenesis. av�3 integrin-avid 
agents have been used to visualize angiogenesis in post-infarct animal models. 
[111 In]- or [1231]-labeled av�3 integrin-avid radiotracer has been shown to be 
focally retained in hypo-perfused myocardial regions [58, 114]. av�3 integrin has 
high binding affinity to arginine-glycine-aspartate (RGD) amino acid sequence 
facilitating cell-extracellular matrix interactions. It has been shown in many 
oncological and myocardial remodeling studies that radiotracers based on RGD 
can be applied targeting av�3 integrin [115, 116]. One recent report showed that 
[18F]-RGD PET can show atherosclerotic changes in apoE -/- mice [132] [117]. In 
that report, quantified measures of [18F]-RGD uptake were correlated with [18F]­
FDG PET measures. 
Vascular endothelial growth factor (VEGF) also plays a key role in angiogenesis. The 
radiolabeled antibodies for VEGF have also been used for detecting angiogenesis, 
especially in tumor cells. Other detectable factors involved in the angiogenesis 
process, such as activated endothelial cells and MMP, are potential targets for 
radionuclide imaging of angiogenesis [100,114]. 
Imaging adhesion molecules expression 
Vascular cell adhesion molecule-1 (VCAM-1) and integrins provide suitable 
targets for molecular imaging of adhesion molecules expression in vascular wall. 
VCAM-1 is expressed by endothelial cells, macrophages, and smooth muscle cells 
[118]. VCAM-1 targeting nanoparticles have been used for signal enhancement in 
atheromatous arteries of apoE -/- mice, and magnetic resonance imaging (MRI) 
showed promising results [119]. 
Recently, the same group labeled the same tetrameric peptide with the positron 
emitter [18F]Fluoride for PET imaging and was able to demonstrate early 
atherosclerotic changes in apoE -/- mice [120]. 
CT applications 
Myocardial application 
MicroCT studies of the heart need blood-pool imaging to make the heart contour 
clear. Iodinated triglyceride is a blood-pool agent that remains in the blood for 
hours and is cleared slowly through the hepatobiliary systems. This contrast 
agent, due to its long circulation time, provides the opportunity to select the best 
post-injection time points for imaging and induces good contrast enhancement 
between myocardium and blood (500 HU) [121, 122]. Mukundan et al. [123] studied 
24 I Chapter 1 
another iodinated agent for microCT which showed more contrast enhancement 
between myocardium and blood in the LV (650-700 HU). In another study, a novel 
polymer-coated Bi253 nanoparticle (BPNP) was used as contrast agent for CT 
scanning in mice. This agent showed high stability, high x-ray absorption (fivefold 
more than that of iodinated agents), and more than 2 hours of circulation time. CT 
scan of mice using BPNP as contrast agent showed clear delineation of ventricles 
and vascular structures [124]. 
In order to evaluate remodeling processes after Ml in mouse models, Detombe et 
al. used retrospective gated microCT [125]. The ability to obtain dynamic images, 
and short scanning times (<1 min), quantification, and the ability to monitor the 
same animal during a longitudinal study are promising results of this study. More 
investigations in the future using hybrid imaging systems (e.g. microSPECT and 
microCT) will add more dimensions to current preclinical studies. 
Vascular dynamics 
To investigate the dynamics of myocardial microvessels, Ba5O4 contrast microCT 
has been used for 3-D visualization of the capacitance of intra-myocardial vessels 
during systole and diastole [126]. In this study, the 3-D architecture of microvessels 
was demonstrated. Images also showed that the vascular volume fraction is 
decreased from diastole to systole by 48%, but is not collapsed. 
Vascular calcification 
Atherosclerotic plaque calcification is correlated with total plaque burden and 
future cardiovascular events [127]. Exploring the underlying pathology of plaque 
calcification will suggest the direction for future interventions. It has been 
shown that formation and progression of plaque calcification is correlated with 
inflammation and apoptosis in atherosclerotic plaques [127, 128]. Interestingly, 
it has been shown that microCT can detect plaque calcification in small rodents 
[103, 129]. lsobe et al. demonstrated the feasibility of microCT images in detecting 
plaque calcification in the aorta [103]. Although, they used [99mTc]-Annexin 
microSPECT/CT to detect apoptosis in ApoE-/- mice they did not investigate the 
correlation between calcification and tracer uptake. Further studies using SPECT/ 
CT to correlate different parameters of plaque vulnerability, using SPECT, with 
calcification, detected by CT, can offer a better understanding on the pathology 
underlying plaque calcification. 
Vascular wall calcification in rodents can also be detected by microCT. In one 
study on uremic mice, which have been shown to be a suitable model for vascular 
calcification, calcification of the aorta was detected and quantified by microCT 
[130]. The quantification results proved to be reproducible and well-correlated 
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with ex-vivo histological evaluation. This may provide investigators with a 
promising technique to follow-up and monitor the effects of therapies aiming to 
reverse vascular calcification in patients with chronic renal failure. 
Conclusion 
MicroSPECT(ICT) and microPET(ICT) are powerful tools for elucidating 
fundamental pathophysiological pathways of heart diseases. They provide 
information on cardiovascular processes at the molecular and cellular levels. They 
also offer the opportunity to monitor pharmacological and biological therapeutic 
interventions in preclinical investigations. Moreover, studies on radiotracer 
development for detecting new aspects of cardiovascular pathophysiological 
processes can be investigated in experi men ta I models of ca rd iovascu la r pathology. 
The recent development of hybrid imaging systems, besides providing technical 
improvements in image quality, adds phenotypic data to functional radionuclide 
imaging information. 
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Objectives of this thesis 
The fol lowing aspects of molecu lar imaging of atherosclerotic disease were 
investigated in this thesis: 
• Molecu lar imaging of angiogenesis i n  atherosclerotic plaques (see Chapters 
2 and 3) A novel method to visual ize abundance of VEGF in human 
atherosclerotic plaque (see Chapter 2). 
• Feasib i l ity of microPET imaging of av�3 integr in using a recently developed 
RGD-contain ing tracer (see Chapter 3) 
• Molecu lar imaging of cel l-death- inh ibitory effects of minocycl ine with 
apoptosis- and necrosis-detecting probes (see Chapter 4) 
• Pred ictive val ue of abdominal aortic calcification for myocard ial infarction, 
stroke, and transient ischemic attack (see Chapter 5) 
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Abstract 
Intra-plaque angiogenesis is associated with the occurrence of atherosclerotic 
plaque rupture. Cardiovascular molecular imaging can be used for detection of 
rupture-prone plaques. Imaging with radiolabeled bevacizumab, a monoclonal 
anti-vascular endothelial growth factor (VEGF)-A, can depict VEGF levels 
corresponding with the angiogenic status in tumors. Here we determined 
the feasibility of [89Zr]-bevacizumab imaging for detection of VEGF in carotid 
endarterectomy (CEA) specimens. Five CEA specimens were co-incubated with 
[89Zr]-bevacizumab and aspecific [1 11 ln]-labeled lgG to determine specificity of 
bevacizumab accumulation. In eleven CEA specimens [89Zr]-bevacizumab micro 
positron emission tomography was performed following two hours of incubation. 
Specimens were cut in 4 mm-wide segments and were stained for VEGF and 
CD68. In each segment mean percentage incubation dose per gram (o/olnc/g) 
and tissue-to-background ratio were determined. A 1 0-fold higher accumulation 
of [89Zr]-bevacizumab compared to[l 1 1  ln]-lgG uptake was demonstrated by 
gamma-counting. Mean o/olnc/ghot spot was 2.2 ± 0.9 with a hot spot-to-background 
ratio of 3.6 ± 0.8. There was a significant correlation between segmental tissue-to­
background uptake ratio and VEGF score 
(p = 0.74, P < 0.001 ). In conclusion, it is feasible to detect VEGF tissue concentration 
within CEA specimens using [89Zr]-bevacizumab PET. [89Zr]-bevacizumab 
accumulation in plaques is specific and correlates with immunohistochemistry 
scores. 
Abbreviations 
CEA = carotid endarterectomy; CT = computed tomography; 
o/olnc/g = % incubation dose per gram tissue; PBS = phosphate-buffered saline; 
PET = positron emission tomography; VEGF = vascular endothelial growth factor 
36 I Chapter 2 
Introduction 
Cardiovascular imaging is an invaluable tool for evaluating atherosclerosis and 
provides clinical information needed for assessment of plaque burden, decision 
making, and evaluation of therapeutic efforts. Conventional imaging modalities 
are able to detect anatomical abnormalities within the structure of the vessel wall 
and luminal stenosis. However, most cardiovascular events do not correlate with 
stenosis severity but with rupture in non-stenotic plaques [1 ]. Thus, the accurate 
detection of plaques that are prone to rupture will improve the identification of 
individuals with higher risk of vascular complications. Molecular imaging can 
be applied for targeting and quantification of ongoing biological processes in 
atherosclerotic plaques leading to plaque rupture. 
Intra-plaque release of vascular endothelial growth factor (VEGF) is known to be 
an important process linked with plaque vulnerability [2]. Both VEGF and local 
hypoxia, result predominantly in chemotactic processes within plaques. This 
process leads to formation of immature blood vessels and subsequent intra­
plaque hemorrhage, thereby causing plaque instability. Clinical detection of 
intra-plaque concentration of VEGF may be used for the assessment of plaque 
vulnerability. 
The role of molecular imaging techniques in detection of angiogenesis has been 
widely investigated in animal and experimental human studies targeting different 
molecules like VEGF [3] , VEGF-receptors [4], and integrins [5]. Radiolabeling of 
the humanized monoclonal antibody bevacizumab for targeting of all VEGF-A 
isoforms can provide a nuclear imaging tracer and can be used to quantify VEGF 
levels in tumors [6] , to show evidence of angiogenesis, and to monitor therapeutic 
efforts targeting VEGF [7, 8]. Previously we showed specific uptake of [89Zr]­
bevacizumab in a high VEGF-secreting human SKOV-3 ovarian tumor xenograft in 
mice [3]. Angiogenesis imaging in patients with melanoma lesions demonstrated 
a strong correlation between semi-quantitative [11 1  ln]-bevacizumab uptake and 
VEGF expression in tumor [6]. 
In this study, we investigated whether [89Zr]-bevacizumab VEGF imaging is 
feasible to detect VEGF in human carotid endarterectomy (CEA) specimens. We 
applied a method for ex vivo nuclear imaging of human CEA specimens that has 
recently been developed by our group and takes advantage of high resolution 
small animal positron emission tomography (PET)  technology in visualization of 
molecular and cellular processes within atherosclerotic plaques [9]. 
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Materials and Methods 
Study design and specimens 
This study was designed according to previous work of our group [9] which 
demonstrated feasibility of ex vivo molecular imaging of CEA specimens after 
incubation in a solution containing tracer followed by high-resolution micro PET 
scan to visualize tracer uptake with great detail. The study was approved by the 
institutional ethics review board of the University Medical Center Groningen, 
Groningen, the Netherlands. Eleven CEA specimens were included from 11 
patients who underwent CEA because of significant symptomatic carotid artery 
stenosis between June 2009 and August 2010. Risk factors and diagnostic data 
for individual patients are shown in Table 1. The samples contained the carotid 
bifurcation, the distal segment of common carotid artery, and proximal segments 
of both the internal and external carotid arteries. Excised non-atherosclerotic renal 
artery obtained from a patient undergoing a kidney transplantation procedure 
was used as a negative control. 
Micro PET procedure 
Bevacizumab (Avastin, 25 mg/ml; Roche, Mijdrecht, The Netherlands) conjugation 
and labeling with [89Zr] (half-life = 3.27 d), from IBA Molecular, was performed 
as described previously [1 OJ. For the preparation of incubation buffer, [89Zr]­
bevacizumab (6.9 ± 4.0 MBq, 30 µg) was diluted in 1 O ml phosphate-buffered 
saline (PBS). Immediately after excision, the specimens were transported under 
sterile conditions and subsequently incubated with [89Zr]-bevacizumab for two 
hours at room temperature. Before the microPET procedure, the plaques were 
flushed 3-5 times with PBS and fixed in a humid box to prevent dehydration. All 
specimens were fixed on a bed and scanned using a microPET focus 220 camera 
(Siemens Preclinical Solutions, Knoxville, TN, USA, Inc.) for 30 minutes. Thereafter, 
a microCT scan was performed using a microCAT I I  system (Siemens Preclinical 
Solutions, Knoxvil le, TN, USA) using the same fixed bed, so the stereotactic position 
was maintained. MicroPET images were corrected for scatter and reconstructed 
applying an iterative reconstruction algorithm (OSEM 2D). 
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Patient 
no. Sex Age Symptom Degree Dyslipidemia Diabetes Hypertension Smoking 
Stenosis 
1 M 69 Amaurosis 50-70 0 0 0 0 
Fugax 
2 M 78 Amaurosis 70-99 1 
Fugax 
3 M 74 TIA 70-99 0 0 1 0 
4 M 65 CVA 80-99 1 0 1 1 
5 M 80 CVA 80-99 0 0 0 0 
6 M 67 CVA 80-99 0 1 0 
7 F 75 CVA 80-99 0 0 1 0 
8 M 79 TIA 80-99 1 1 1 0 
9 M 66 TIA 70-99 1 0 0 0 
10 M 44 CVA 70-99 1 0 0 0 1 1  M 82 TIA 70-99 0 1 0 
Table 1. Jndividua/ patient data, risk factor, and diagnostic data. 
Dyslipidemia: 0 = chlolesterol and triglyceride within normal range, 1 = controlled with treatment; 
diabetes: 0 = non-diabetic, 1 = diagnosed diabetes mellitus; hypertension: O = none, 1 = hypertension; 
smoking: 0 = non-smoker, 1 = currently (includes abstinence < 1 year) 
CVA = cerebrovascular; TIA = transient ischemic attack 
Determination of specific uptake 
111 In (Covidien, Petten, The Netherlands) -labeled human lgG (Sanquin, 
Amsterdam, The Netherlands) was used as an a-specific control antibody as 
described previously [1 OJ . A mixed dose of [89Zr]-bevacizumab and [111 ln]-lgG (5 
± 0.5 MBq, 0.3ml; diluted in 10 ml PBS) was prepared and five control specimens 
were incubated. After two hours, specimens were washed with PBS and were 
counted in a calibrated well-type LKB-1282-Compu-gamma-system (LKB Wallac, 
Turku, Finland) using dual-isotope counting program for both isotopes. The 
overlap of [89Zr] counts in [111 In] channel was corrected. The activities of [89Zr] 
and [111 In] were calculated as percentage incubation dose per gram (%Inc/g). 
lmmunohistochemistry 
After the scan, specimens were oriented on a flat surface and were serially cross­
sectioned in 4 mm slices and numbered from proximal to distal. The sections were 
formalin-fixed and paraffin-embedded, and sectioned at 5 µm. The tissue slides 
were blocked with 0.3% H2O2, followed by blocking endogenous avid in and biotin 
(SP-2001; Vector Laboratories; Burlingame, CA) and were incubated with rabbit 
anti-VEGF antibody A-20 (diluted 1 :50; Santa Cruz Biotechnology, Santa Cruz, CA) 
for one hour at room temperature. Subsequently the slides were incubated with 
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biotinylated goat anti-rabbit antibody (diluted 1 :300; DAKO), followed by ABC 
Elite (diluted 1:100; DAKO). Antibody detection was performed with the DAB kit 
(DAKO). The sections were counterstained with hematoxylin for two minutes. In 
five sections macrophage content was evaluated by CD68 immunostaining and 
antibody was detected with the DAB kit to discover co-localization between VEGF 
and macrophage presence. 
All sections were examined on a blind basis using a light microscope with the 40x 
objective. The level of VEGF staining was scored from 0-3, determined by semi­
quantitative combined assessment of the percentage of stained cells and the 
staining intensity as described before [1 1 ]. 
CD68 staining was categorized semi-quantitatively according to a commonly 
used and reproducible method as described previously [9]. 
Data analysis 
Because of the short time difference between incubation and scanning, radioactive 
decay was considered negligible for both [89Zr] and[l 1 1  In]. MicroPET and microCT 
images were registered using AMIDE software (version 0.9. 1, Stanford University) 
and a whole specimen 3-dimensional region of interest (ROI) was drawn manually 
in microCT images and was applied to microPET images. The mean %Inc/g in 
total specimen was calculated. The maximal uptake of [89Zr]-bevacizumab 
within the specimen was determined and the hot spot was defined using a three­
dimensional isocontour ROI with a threshold of 70% maximal uptake. 0/olnc/g in 
hot spot was calculated (%Inc/ghat spot). To obtain a background value for [89Zr]­
bevacizumab uptake, %Inc/g was measured in a manually drawn ROI within 
a specimen adjacent to the hot spot. Segmental ROls were drawn manually in 
accordance to immunohistochemical slices to compare tracer accumulation with 
immunohistochemistry. In each segment a segmental %Inc/gmean was calculated 
and tissue-to-background ratio was calculated by dividing segmental %Inc/gmean 
by background tracer accumulation of the same specimen, as described above. 
Categorical measures of VEGF and CD68 staining were compared using the Chi­
squared test. 
Statistical analysis 
Quantitative results were shown as mean ± SD. Regression analysis was used to 
determine relationships between mean %Inc/g in specimen and specimen size. 
%Inc/g and tissue-to-background ratio of [89Zr]-bevacizumab uptake in each mean 
segment was compared with semi-quantitative measures of VEGF-A staining 
and the results were tested by use of Spearman correlation coefficients (p). 
Per specimen analysis was performed by calculating average VEGF-A staining scores, 
0/olnc/g, and tissue-to-background ratio of the stained segments of each specimen. 
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Results 
Feasibility 
The mean length of the specimens was 2.4 ± 0.7 cm. The specimens were 
transported from the operation room to the lab within 10 minutes after excision. 
In all CEA specimens clear [89Zr]-bevacizumab uptake within arterial wall was 
seen (Figure 1 ). [89Zr]-bevacizumab uptake in all plaques was heterogeneously 
distributed. The mean o/olnc/gh t was 2.2 ± 0.9, the mean o/olnc/g in specimen was o spot 
0.9 ± 0.4 (ranging from 0.44 to 1.99), and the mean o/olnc/g in the background was 
0.6 ± 0.3. Average hot spot-to-background ratio within the CEA specimens was 
3.6 ± 0.8. No correlation was found between plaque size and [89Zr]-bevacizumab 
uptake (p = 0.41; P = 0.2). The mean o/olnc/g in the negative control arterial tissue 
was 0.18%. 
Specific Uptake 
In five specimens the specificity of [89Zr]-bevacizumab uptake was evaluated. 
For this purpose, co-incubation was performed using both [89Zr]-bevacizumab 
and control [111 ln]-lgG. Quantitative measurements of both tracers by gamma­
counter showed that [89Zr]-bevaciumab uptake was 10 fold higher when 
compared with the control [111 ln]-lgG (1.9 ± 0.9 o/olnc/g and 0.2 ± 0.1 o/olnc/g, 
respectively; P = 0.01 ). 
VEGF Staining, Tracer Uptake, and Macrophage Content 
In 35 slices of the CEA specimens VEGF staining was performed 
(Figure 2). Segmental o/olnc/g and tissue-to-background ratio in each group of mean 
VEGF staining is shown in Table 2. 
Figure 1.  (A) MicroPET image of 89Zr-bevacizumab uptake in human CEA specimen. (B) MicroCT of a 
human CEA specimen. (C) Fused microPETICT. (D) Transverse view of microPET image shows high tracer 
accumulation within arterial wall. 
CEA = carotid endarterectomy; CT= computed tomography; PET= positron emission tomography 
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Negative 2 3 
VEGF score 
Control 
Number (total) 6 15 13 
Tissue-to- 1.54 2.00 2.41 
background ratio 
96Inc/�e.nn 0.18 0.85 1.03 1.21 
Table 2. Mean segmental 89Zr-bevacizumab uptake values in segments with different VEGF staining 
scores. VEGF score was determined according to semiquantitative combined assessment of the 
percentage of stained cells and the staining intensity as described in (1 1 ). 
%/nc/g = % incubation dose per gram tissue; 
VEGF = vascular endothelial growth factor. 
Figure 2. (A) Coronal view of CEA specimen. Dashed lines show the levels of tranverse views. 
(B 1) lmmunohistochemistry of a slide with high bevacizumab uptake shows intensive staining of VEGF 
in CEA specimens. (82) lmmunohistochemistry of a slide with low bevacizumab uptake shows weak 
staining. CEA = carotid endarterectomy; VEGF = vascular endothelial growth factor. 
In total stained segments the segmental %Inc/g was 1.05 ± 0.39 and tissue-mean 
to-background ratio was 2.05 ± 0.6. Association between VEGF score and 
segmental %Inc/g (p = 0.29, P < 0.05) and tissue-to-background ratio of mean 
[89Zr]-bevacizumab uptake (p = 0.74, P < 0.00 1 )  were determined by Spearman 
correlation analysis (Figure 3a). 














Figure 3. (A) The correlation between VEGF score with segmental %/nc/gmean (black bars; p = 0.29, 
P < 0.001). (8) Per specimen correlation between average tissue-to-background ratio and VEGF scores 
in the stained specimens (Spearman's rank correlation) %/nclg = % incubation close per gram tissue, 
VEGF = vascular endotherlial growth factor. 
Plaque Mean Mean Mean 
number VEGF score %Inc/g Tissue-to-
background ratio 
1.80 1.13 1.94 
2 1.33 1.02 1.51 
3 2.00 1.15 1.83 
4 2.33 o.86 2.40 
5 140 0.81 1.64 
6 2.75 0.72 2.00 7 3.00 1.23 3.16 8 2.67 0.84 2.10 
9 3.00 2.25 2.81 
Table 3. Average VEGF score, %/nclg, and average tissue-to-background ratio ofVEGF stained 
segments in each specimen. %/nc/g = % incubation close per gram tissue, VEGF = vascular endotherlial 
growth factor. 
Per specimen analysis was performed in nine specimens. Average VEGF scores, 
o/olnc/g, and tissue-background ratio of each specimen is shown in Table 3. 
Spearman's correlation analysis showed an excellent correlation between average 
tissue-to-background ratio and average VEGF score (p = 0.91, P < 0.01, Figure 3b), 
however there was no correlation found between average o/olnc/g and average 
VEGF score in CEA specimens (data not shown). 
In order to evaluate the cellular basis of VEGF release, CD68 staining was performed 
in eight sections and showed a co-localization between sub-endothelial 
macrophage content and VEGF staining (Figure 4). The Chi-square test showed 
that the sections did not differ in VEGF and CD68 staining scores (P = 0.45). 
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Discussion 
In the present study we showed for the first time the feasibility of ex vivo [89Zr]­
bevacizumab VEGF imaging in human CEA specimens. Here, we report the 
promising features of radiolabeled anti-VEGF PET in atherosclerotic plaques. 
Accumulation of the tracer was size-independent and heterogeneously 
distributed within the plaque with a high signal-to-background ratio. The average 
mean o/olnc/g in CEA specimens was 5 times higher than mean o/olnc/g in a normal 
artery. Moreover, a high specific uptake was demonstrated as we showed a 10-
fold higher accumulation of [89Zr]-bevacizumab compared to control [111 ln]-lgG 
using dual-isotope gamma-counting and size-independent uptake. Furthermore, 
we showed that the mean activity accumulation in the plaque correlates with 
the tissue VEGF abundance, determined by immunohistochemistry. Our finding 
suggests the possibility of designing further clinical studies to assess the role of a 
VEGF-targeting tracer to obtain PET images in stratifying the risk of patients with 
atherosclerotic disease. 
[18F]-FDG PET imaging has been proposed for detecting macrophage content 
and vulnerability in atherosclerotic plaques [12]. However, the fact that [18F]­
FDG accumulates in any highly-metabolizing cell results in suboptimal specificity 
in depicting vessel wall inflammation [13]. Detection of VEGF activation, a 
pathophysiologically relevant indicator of macrophages and an independent 
determinant of plaque vulnerability might offer the opportunity to track both 
vessel wall inflammation and angiogenesis in atherosclerosis. This study has 
shown a co-localization and similar intensity scores of VEGF and CD68 (a marker 
of macrophages) in CEA specimens, however in accordance with previous studies 
VEGF was also abundant in areas with numerous smooth muscle cells and within 
extracellular matrix [14]. This result emphasizes the link between inflammation 
and angiogenesis in atherosclerotic plaques, and raises the possibility that VEGF­
targeted imaging could provide indirect information on plaque inflammation 
correlated to its vulnerability in vivo. The predictive role of [18F]-FDG PET or 
VEGF-targeted imaging with plaque vulnerability and rupture needs to be further 
investigated and compared. 
Although it has been suggested by some studies that VEGF may also have 
a potential beneficial role on atherosclerotic disease through regeneration 
of endothelium and endothelial function improvement [1 SJ , a large body of 
evidence underlines substantial role of VEGF in maintenance and destabilization 
of atherosclerotic plaques rather than its protective effects [16]. 
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Figure 4. A, Four times magnification of vascular endothelial growth factor (VEGF)-stained cells. 8, Four 
times magnification of CD68 staining in the same piece showing intense subendothelia/ macrophage 
content with a pattern similar to that ofVEGF staining. C, Ten timesmagnification of VEGF staining and, 
D, ten times magnification of C068 staining in the same slides (black arrows). The co/ocalization of 
VEGF and CD68 can be clearly identified. This finding suggests a combined role of both 
biomarkers in the inflammatory process of the vulnerable plaque. 
Thus, the ability to image VEGF within plaques by PET can offer a promising tool for 
evaluating vulnerability and monitoring therapeutic efforts aiming stabilization 
of atherosclerotic plaques. In previous investigations the value of radiolabeled 
bevacizumab imaging was shown in detection of VEGF in VEGF-secreting tumors 
[3, 6-8]. 
Adequate preservation of binding affinity of [89Zr] labeled bevacizumab 
was previously shown by our group using a VEGF-coated enzyme-linked 
immunosorbent assay [3]. In vitro evaluation of binding affinity showed 54% ± 
3.7% binding of [89Zr]-bevacizumab to VEGF-coated wells. Additions of 500 fold 
excess unlabeled bevacizumab for competition assay resulted in almost complete 
blocking of radiolabeled bevacizumab binding (<5%, ranging from 1 %-4%) 
comparable with non-specific binding of radiolabeled lgG (4%-8%). 
Specificity of radiolabeled bevacizumab uptake was previously shown in a study 
by our group on human tumor xenografts [3] and indicated VEGF-mediated [89Zr]­
bevacizumab uptake. In order to verify specificity of [89Zr]-bevacizumab uptake 
in CEA specimens, we were not able to execute the frequently used approach 
of blocking specimens using an excess of the unlabeled bevacizumab, as it has 
been shown that incubating the specimens with unlabeled bevacizumab could 
cause functional changes in tissue and influence on pathobiological properties 
of CEA specimens [ 1 7]. In this study, instead, we co-incubated the specimens in 
equal doses [89Zr]-bevacizumab and aspecific [ 1 1 1  ln]-lgG, as a control. Samples 
were counted for radioactivity by using a dual isotope gamma-counting program 
in a calibrated well-type gamma-counter, the same method used in a previous 
report by our group [ 1 8, 1 9]. The results showed 1 0  fold higher accumulation of 
[89Zr]-bevacizumab than that of [ 1 1 1  ln]-lgG. Moreover, normal arterial tissue was 
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incubated in [89Zr]-bevacizumab and showed five times less accumulation of 
bevacizumab which further confirms specificity of the tracer. 
Another approach in visualization ofVEGF pathway and evaluation of angiogenesis 
is molecular imaging of VEGF-receptor. In vivo imaging with radiolabeled VEGF 1 2 1  
([64Cu]-DOTA-VEGF 1 2 1 ) has successfully demonstrated the ability to depict VEGF­
receptor in mouse model of human glioblastoma tumor [4]. Recently, an easy­
to-label [68Ga]-labeled tracer, based on engineered single-chain VEGF, has been 
developed and showed promising characteristics for imaging VEGF-receptor 
in angiogenic vasculature [20]. Given that the correlation between VEGF tissue 
concentration and VEGF-receptor expression and the corresponding role of their 
levels in progression of angiogenesis is not well-determined, the two methods for 
imaging and quantification of VEGF and VEGF-receptor can be complementary in 
evaluating angiogenesis in vivo. 
Although mean segmental o/olnc/gmean and mean tissue-to-background ratio 
in different VEGF scores showed a trend to superior accumulation of [89Zr]­
bevacizumab uptake in higherscoresofVEGF (Figure 3), therewasa weak correlation 
between mean segmental o/olnc/g and VEGF immunohistochemistry scores. mean 
Per specimen analysis also showed that despite an excellent correlation 
between mean tissue-background ratio in the stained sections, there is no 
association between average o/olnc/g and average VEGF scores in the specimens. 
This may partially be explained by semi-quantitative measurements of 
immunohistochemistry results. Moreover, VEGF staining shows cytoplasmic 
and macrophage-bound VEGF, though it is not very sensitive in accounting 
for detection of VEGF secreted into the extracellular matrix. On the contrary, 
[89Zr]-bevacizumab has a high affinity to all VEGF-A isoforms including those 
secreted into the extracellular matrix. In order to overcome this difference in 
targeting VEGF, we compared semi-quantitative immunohistochemistry results 
with semi-quantitative microPET measures of tissue-to-background ratio. The 
results showed a good correlation between segmental tissue-to-background 
ratio and VEGF staining level (spearman p = 0.74) and specimen average tissue­
to-background ratio and specimen average VEGF staining score (spearman p 
= 0.91 ). A better correlation between VEGF scores with relative measures of 
[89Zr]-bevacizumab accumulation (tissue-to-background ratio) rather than 
absolute measures of tracer accumulation could also be explained by the fact 
that variability in the tracer dose in incubation buffer (6.4 ± 4.0 MBq) can result 
in different accumulation of bevacizumab in normal tissue within the specimens. 
However, tissue-to-background ratio corrects the quantitative imaging data for 
possible variation in pharmacokinetic behavior of [89Zr]-bevacizumab in normal 
tissue due to wide range of tracer dose. In addition, the fact that segmental %Inc/ 
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g was compared with VEGF immunohistochemistry score on a Sµm section 
mean 
of a 4mm-wide segment, which cannot represent total VEGF level within the 
segment, is an acknowledged limitation of this study. Tissue extract ELISA can 
provide more precise information on VEGF levels in corresponding segments of 
microPET images, in future studies. 
It has been reported in tumor xenografts that due to the long half-life of 
bevacizumab in blood (17-21 d) and its slow pharmacokinetics, the optimal 
imaging time, which provides the highest target-to-blood ratio is 4 to 7 days after 
tracer injection. In our study, we targeted VEGF ex vivo; therefore a long incubation 
time was not necessary. Future studies should be designed to determine the 
optimal imaging time point after tracer injection that provides the highest 
target-to-blood ratio in humans. Furthermore, future application of fluorescent 
or radiolabeled bevacizumab as well as other VEGF targeted tracers in coronary 
artery disease requires a high target-to-heart uptake ratio. In a previous work of 
our group we observed a specific uptake value of 3.43% ± 0.99 % in mouse heart 
at 24 hours after injection which rapidly declined over time (2.31 % ±0.93% at 72 
hours and 2.11 % ± 0.66 % at 168 hours) [3]. In our study average o/olnc/ghot spot of 
[89Zr]-bevacizumab at two hours was 2.2 ± 0.9. We predict an increase in plaque 
uptake of [89Zr]-bevacizumab over time which remains high at 72-168 hours, with 
the same pattern that we observed in tumors. However, this prediction needs to 
be tested explicitly. 
Given that bevacizumab is a recombinant humanized monoclonal antibody and 
species-specific, it is not possible to investigate the role of [89Zr]-bevacizumab 
in viable rodent models of atherosclerosis, namely apoE deficient and LDL 
receptor deficient mice. However, in a recent study on immuno-deficient 
mice transplanted with human coronary artery tissue, it has been shown that 
bevacizumab treatment ameliorates vascular remodeling through VEGF blockade 
[21]. [89Zr]-bevacizumab imaging in this animal model can provide a unique 
approach to investigate feasibility of humanized monoclonal antibody imaging 
in atherosclerotic disease in vivo. The biodistribution of bevacizumab in mice 
was earlier investigated by our group and showed a low muscle accumulation of 
the tracer which is a promising property for imaging carotid arteries and could 
offer the opportunity to depict lesions with a high target-to-muscle ratio [3]. 
Additionally, in a clinical study by our group, accumulation of 
[89Zr]-bevacizumab was calculated in different organs in patients with renal cell 
carcinoma [22]. Mean specific uptake value of [89Zr]-bevacizumab in human 
muscle tissue was 0.47 ± 0.15 % injected dose per gram which makes the tracer a 
promising probe for imaging carotid arteries in human, due to low tracer uptake 
in surrounding muscle tissue. 
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The current study provides evidence that bevacizumab imaging for depiction of 
tissue abundance of VEGF in atherosclerotic plaques is feasible. In order to expand 
upon observations of this study in human in vivo imaging, blood clearance of 
the tracer should be measured and dosimetry should be performed to provide 
further information on potentials of [89Zr]-bevacizumab application in a clinical 
setting. Besides, due to high radiation burden associated with [89Zr]-labeled 
probes it seems reasonable to label VEGF-targeted probes with isotopes with 
shorter half-life and lower radiation energy like [18F] to impose less radiation 
burden to patients undergoing imaging. Bevacizumab is not feasible to carry PET­
tracers with a shorter half-life because of its long biological half-life. Future pilot 
studies on in vivo imaging of radiolabeled or fluorescent VEGF-targeted probes 
can provide further information on potentials of bevacizumab radionuclide 
imaging in cardiovascular diseases. 
It could also be of interest to use radiolabeled ranibizumab, a monoclonal 
antibody fragment derivative of bevacizumab which has a serum half-life of 2 to 
6 hours for detection of VEGF signaling in human plaques. The latter could be 
clinically more favorable, as [89Zr]-bevacizumab takes at least 2-3 days before 
imaging and is associated with an unacceptable high radiation burden. It has 
been shown in a recent study on mouse xenograft models of human cancer that 
[89Zr]-ranibizumab-PET allows rapid visualization of VEGF with high affinity to all 
VEGF-A isoforms [23]. 
Rapid blood clearance and maximal tumor uptake within 24 hours make 
ranibizumab a promising tracer for future human studies. Theoretically, [18F]­
labeled ranibizumab would result in more optimal tracer kinetics as well as a large 
decrease in the radiation burden, since the radiation burden associated with 
[89Zr]-labeled probes is too high. 
Beside the use of radiolabeled bevacizumab, the use of targeted fluorescent 
imaging could be of interest for imaging VEGF in atherosclerotic plaques. In a 
recent study, we demonstrated that IRDye 800CW labeled bevacizumab showed a 
high specificity and sensitivity in detecting VEGF in tumor models in vivo [24]. The 
possibility to detect sub-millimeter lesions with an intra-operative near infrared 
camera matches the structural characteristics of carotid atherosclerosis. Moreover, 
anatomical exteriority of carotid artery provides the opportunity to overcome the 
drawback of fluorescent imaging in lack of penetration. 
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Conclusion 
This study illustrates the potential of VEGF as a target for visualization of 
pathobiological processes in development of atherosclerosis. Specifically, 
heterogeneous [89Zr]-bevacizumab accumulation within plaques was observed. 
Non-invasive imaging of VEGF could provide clinicians a new and perhaps a better 
tool in determination of individuals with higher risk for cardiovascular events. 
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Background: Given the fact that angiogenesis plays an important role in 
atherosclerotic plaque vulnerability, molecular imaging of angiogenesis can be 
used for determination of rupture-prone atherosclerotic plaques. av�3 integrin 
is a key player in the process of angiogenesis. Targeted imaging of av�3 integrin 
has been shown to be possible in previous studies on tumor models, using 
radiolabeled arginine-glycine-aspartate-(RGD). Our aim was to investigate 
feasibility of ex vivo detection of av�3 integrin in human carotid endarterectomy 
(CEA) specimens. 
Methods: Nineteen CEA specimens, immediately after excision, were incubated in 
5 MBq [18F]RGD-K5 for one hour followed by 1 hour emission microPET scan. The 
results were quantified in 4 mm wide segments as percent incubation dose per 
gram (o/olnc/g). A segmental-to-total ratio was calculated by dividing segmental 
o/olnc/g by total specimen's o/olnc/g. Presence of av�3 integrin and endothelial 
cells in each segment was confirmed by immunohistochemical staining for CD31 
and av�3 integrin, respectively. 
Results: [18F]RGD-K5 uptake was heterogeneous in CEA specimens and was 
localized within the vessel wall. Significant correlations were observed between 
segmental-to-total ratio with av�3 integrin staining score (r = 0.58, p = 0.038) and 
CD31 staining score (p = 0.67, P < 0.002). 
Conclusion: This study, for the first time showed the feasibility of integrin imaging 
in determination of av�3 integrin expression and angiogenesis in human 
atherosclerotic plaques. 
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Introduction 
Hemorrhage formation within the atherosclerotic lesion as a consequence of intra­
plaque pathology has been linked to vulnerability of atherosclerotic plaques to 
rupture and further cardiovascular complications [1 ]. Most cardiovascular events 
(including heart attacks and strokes) result from plaque rupture in non-stenotic 
atherosclerotic plaques [2]. So, there is a need to develop non-invasive methods 
for detection of rupture-prone plaques. By this means an individualized means 
for clinicians to risk stratify patients at higher risk for cardiovascular events can be 
provided. One of the possible methods to achieve this goal would be to establish 
molecular imaging methods for this purpose. 
Molecular imaging of angiogenesis targets variable players in the process of 
angiogenesis. Vascular endothelial growth factor (VEGF) [3], VEGF-receptor [4], 
and integrins [5] have been targeted by molecular imaging probes and imaging 
studies have shown promising results in detection of angiogenesis in oncology 
research. Among integrin proteins, specifically av�3 integrin, a cell surface 
receptor, plays a crucial role in process of angiogenesis by mediating adhesion of 
cells to extracellular matrix and migration of endothelial cells [6]. Because of its 
critical role, av�3 integrin imaging has been a focus of many studies. 
The tripeptide sequence arginine-glycine-aspartate- (RGD-) containing integrin 
ligands have a large number of medical applications ranging from non-invasive 
visualization of integrin expression in vivo to the synthesis of functionalized 
biomaterials. Over the past decade, a variety of radiolabeled cyclic peptide 
antagonists with structures based on the RGD sequence have been evaluated 
as integrin av�3-targeted radiotracers [7]. The PET tracers [18F]Galacto-RGD, 
[18F]-AH111585 and [18F]RGD-KS are currently under clinical investigation for 
visualization of integrin av�3 expression in cancer patients [8-12]. 
It has been shown that small animal positron emission tomography (PET) imaging 
of av�3 integrin is possible in highly av�3 integrin-expressing mouse tumors and 
mouse models of human tumor xenografts with a high tumor-to-background 
ratio and specificity [13]. The role of a single photon emission computed 
tomography (SPECT) [99mTc]-RGD-based probe in detection of inflammation 
in mouse models of vascular remodeling has been demonstrated recently [14]. 
Moreover the link between [18F]-galacto-RGD uptake and inflammation has 
been recently demonstrated in mouse models of atherosclerosis [15]. In another 
study the feasibility of [99mTc]-RGD-based imaging was showed in patients with 
myocardial infarction [16]. 
In this study, we investigated whether it is feasible to detect av�3 integrin in 
human carotid endarterectomy (CEA) specimens using an ex vivo imaging 
method recently developed by our group [17]. This method allows using high 
resolution microPET system to illustrate heterogeneous tracer uptake within 
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atherosclerotic plaque and correlating tracer uptake with pathologic finding of 
plaques in different regions. For this purpose we used a recently developed [18F]­
labeled RGD compound, which is produced using a click chemistry method. 
Materials and Methods 
Study design and specimens 
This study was designed according to previous work of our group on incubation 
of CEA specimens immediately after excision with radio-tracer followed by 
ex vivo high-resolution microPET scan to visualize tracer uptake with great 
detail [17]. The study was approved by the institutional ethics review board of 
the University Medical Center Groningen, Groningen, the Netherlands. CEA 
specimens were included from 19 patients who underwent CEA because of 
significant symptomatic carotid artery stenosis between January 2011 and June 
2012. In order to determine specificity of tracer uptake, in three CEA specimens 
blocking study was performed using an excess dose of cold compound followed 
by microPET imaging. 
Reagents 
Reagents and solvents were obtained from commercial suppliers (Aldrich, Fluka, 
Sigma, and Merck) and used without further purification. RGD-K5 azide and 
19F-RGD-K5 were synthesized by Siemens Molecular Imaging Biomarker Research 
(Culver City USA). HPLC analysis was performed with an Elite LaChrom VWR Hitachi 
L-2130 pump system (Darmstadt, Germany) connected to a UV-spectrometer 
(Elite LaChrom VWR Hitachi L-2400 UV detector) and a Bicron frisk-tech radiation 
detector. For the analysis of radiolabeled compounds, the HPLC elutes after 
passage through the UV detector was led over a 3 inch Nal (TI) scintillation detector 
(Wallac, Turku, Finland) connected to a multi-channel analyzer (Gabi box, Raytest, 
Straubenhardt Germany). The output signal was recorded and analyzed using a 
GINA Star data acquisition system (Raytest, Straubenhardt, Germany). 
Synthesis of [1 BFJRGD-K5 
A solution of pent-4-ynyl-4-methylbenzenesulfonate (20-25 mg, 84-105 µmol) 
in 0.8-1 ml anhydrous 1,2- dichlorobenzene was added to anhydrous Kryptofix 
2.2.2 K[18F]F residue and the mixture was heated for 10 min at 110 oC to provide 
[18F]-fluoropentyne which was simultaneously distilled with a gentle flow 
of helium to a second reactor containing the click reaction mixture. The click 
reaction mixture contained 0.1 mg RGD-K5 azide precursor (2-((2S,5R,8S, 11 S)-
8-(4-( (3S,4S,SR,6R)-6-((2-azidoacetamido)methyl)-3,4,5-trihydroxytetrahydro-
2H-pyran-2-carboxamido)butyl)-5-benzyl-11-(3-guanidinopropyl)-3,6,9, 12, 15-
pentaoxo-1,4,7, 10, 13-pentaazacyclopentadecan-2-yl)acetic acid; TFA salt) in the 
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presence of 0.2 mg phosphoramidite Monophos, 1 mol % (0.05 mg) CuSO4.5H2O 
(reduced to Cu(I) with 5 mo!% (0.25 mg) sodium ascorbate), in either 0.25 ml EtOH 
and 0.25ml CH3CN. After reacting at room temperature for 10 min, the crude 
[18F]RGD-K5 was diluted with 1.5 ml of 0.025 M Na2HPO4 pH 7 and purified by 
semi-preparative RP-HPlC using an XBridge Cl 8 column (5 µm, 4.6 mm x 150 mm 
column, Waters) eluted with 0.025M Na2HPO4 pH 7.0 and EtOH 86/14 at a flow 
rate of 4 ml/min. UV detection of the HPlC eluate was performed at 254 nm. [18F] 
RGD-K5 was collected after 20-25 min. Purified [18F]RGD-K5 was collected in a 
1.3-2.6 ml volume (mobile phase). This HPlC-purified fraction was diluted with 
preparative HPlC mobile phase and passed through a sterile, apyrogenic 0.22 µm 
membrane filter (Millex®-GV, Millipore, Ireland). A final solution of 370 MBq/ml 
was obtained by further dilution with saline, which was passed through the same 
membrane filter. 
Quality control procedures 
QC was performed on a Phenomenex Prodigy Cl 8 column (5 µm, 4.6 mm x 150 
mm column with CH3CN and water (40:60 v/v) in the presence of 0.1 % TFA as 
eluent at a flow rate of 3ml/min. The radiochemical identity of [18F]RGD-K5 was 
confirmed using authentic RGD-K5 as an external reference material. 
Micro PET procedure 
For the preparation of incubation buffer, [18F]-RGD-K5 (5.1 MBq ± 0.2, 100µ1) was 
diluted in 15 ml phosphate-buffered saline (PBS). CEA specimens were incubated 
for 1 hour in the incubation buffer at room temperature. After 1 hour the plaques 
were rinsed 3-5 times with PBS and positioned and fixed in a humid box on 
microPET bed. All specimens were scanned using a microPET focus 220 camera 
(Siemens Preclinical Solutions, Knoxville, TN, USA, Inc.) for 60 minutes. Thereafter, 
a microCT scan was performed using a microCAT II system (Siemens Preclinical 
Solutions, Knoxville, TN, USA) as the stereotactic position was maintained. 
MicroPET images were corrected for scatter and reconstructed applying an 
interactive reconstruction algorithm (OSEM 2D). 
lmmunohistochemistry 
Specimens were serially cross-sectioned in 4 mm slices and numbered from 
proximal to distal. Formalin-fixed paraffin-embedded 5 µm-cut slides were made 
and were stained for av�3 integrin and CD31 (as a marker for endothelial cells). 
The level of staining was semi-quantitatively scored by combined assessment of 
distribution of stained cells and staining intensity based on overall appearance of 
slides based on a 0-3 score scale. 
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In summary, intensity was scored from O = absent, 1 = weak, 2 = intermediate and 
3 = strong staining. Percentage positive cells were scored based on a 3-scoring 
scale. Scores for intensity and percentage were summed up and produced a total 
score O through 6. Further, final semi-quantitative scored were defined as O = total 
score 0, 1 = total score 1 and 2, 2 = total scores 3 and 4, and 3 = total score 5 and 6. 
Data Analysis and Statistics 
Tracer uptake in microPET images was corrected for radioactive decay and 
background. MicroPET and microCT images were registered using AMIDE 
software (version 0.9.1, Stanford University) and a whole specimen 3-dimensional 
region of interest (ROI) was drawn manually on microPET images. The mean 
percent incubation dose per gram in total specimen (o/olnc/gtotai) was calculated. 
Segmental ROls were drawn manually in accordance to the cut segments for 
to compare tracer accumulation with immunohistochemistry. In each segment 
a o/olnc/g t 
I 
was measured and ratio of o/olnc/gsegmental to o/olnc/gtotal segmen a 
(segmental-to-total) was calculated for each segment. 
Quantitative results were shown as mean ± SD. Segmental-to-total ratio of [18F]­
RGD-K5 uptake in each segment was compared with av�3 integrin and CD31 
staining and correlation between variables were tested by use of Spearman 
correlation coefficients (p). The Significance level (P) was set at 0.05. 
Results 
Feasibility and Specific Uptake 
Emission microPET scans were performed in 16 CEA specimens of patients who 
underwent surgery for symptomatic stenotic (70%-99%) plaque of carotid artery. 
The samples contained the carotid bifurcation, the distal segment of common 
carotid artery, and proximal segments of both the internal and external carotid 
artery.The mean lengthofthespecimenswas2.1 ±0.6cm. Specimenswerescanned 
following one hour incubation in [18F]-RGD-K5. After image reconstruction clear 
accumulation of tracer in specimens was visible in all specimens (Figure 1 ). [18F]­
RGD-K5 binding was heterogeneous in CEA specimens and was localized within 
vessel wall (Figure 1 ). A 3-dimensional 70% maximum uptake value isocontour ROI 
was drawn to determine hotspot inside the specimen. Mean o/olnc/g in hotspot 
was 1.30% ± 0.34 (ranging from 0.65% to 1.93, and the mean o/olnc/gtotal was 0.45% 
± 0.19 (ranging from 0.14% to 0.77%). Average hotspot-to-total uptake ratio was 
3.19 ± 0.91. 
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Figure 1. Transversal (A), coronal (8), and saggital (C) sections of microPET image of a carotid 
endarterectomy specimen after 1 -hour incubation in [1 BFJ-RGD KS shows heterogeneous uptake along 
specimen. Transversal image shows that area of higher uptake (red) is confined within the vesal wall. 
PET= Positron Emission Tomography 
■ 
CD31 m,P3 Integrin 
Figure 2. Saggital and transversal view of [1 BFJ-RGD-kS microPET image of an excised carotid 
endarterectomy specimen (left). Transversal images, CD3 1 staining (brown), and av/33 integrin staining 
of corresponding slices are shown (1 Ox). 
Blocking experiments were performed in three specimens by incubation of CEA 
plaques in 550 times excess unlabeled compound followed by incubation in 
[18F]-RGD-K5. Using the same protocol, 1 hour after incubation an emission scan 
was performed and mean %Inc/g was calculated to show the effects of blocking 
on the tracer uptake. The results showed a significant decrease (6 times less 
accumulation) of the tracer in CEA specimens (0.45%Inc/g vs. 0.08%Inc/g). 
lmmunohistochemistry 
In a randomly selected series of 13 slices (of six plaques) av�3 integrin staining 
was performed. A very heterogeneous integrin expression was observed among 
the samples. lmmunohistochemical scoring of av�3 integrin staining was done 
according to a semi-quantitative three-score scaling method based on staining 
intensity and amount of stained area. Comparing staining scores and segmental­
to-total ratio showed a moderate but significant correlation as indicated by the 
Spearman's correlation coefficient (r = 0.58, p == 0.038). 
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In 18 slices of six CEA specimens CD31 staining was performed to determine new 
vessel formation (Figure 2). The level of CD31 staining was scored from 0-3, by 
assessment of the percentage of stained cells and the staining intensity. Semi­
quantitative measures of segment-to-total ratio and CD31 staining score is shown 
in table 1. The correlation between CD31 staining score and segmental-to-total 
ratio was significant (p = 0.67, 
P < 0.002). 
Sample CD31 Integrin Segmental -
Score Score to-total ratio 
1 2 2 1.15 
2 2 3 1.14 
3 1 0 0.90 
4 2 1 1.68 
5 1 1.20 
6 1 0 1.058 
7 2 0.78 
8 1 1.06 
9 1 1 1.46 
10 2 1.54 
11 2 2 1.48 
12 3 2 2.62 
13 0 1 0.57 
14 0 0 0.83 
15 1 1 1.25 
16 2 1 1.12 
17 0 1 0.91 
18 0 0.74 
Table 1. Semi-quantified segment-to-total accumulation of 1 BF-RGD KS PET results on and 
immunohistochemistry scores of the corresponding section in human carotid endarterectomy 
specimens. 
Discussion 
Angiogenesis occurs in atherosclerotic plaques due to increase in size and hypoxia 
and leads to formation of immature blood vessels which in turn exacerbates 
inflammation and intra-plaque hemorrhage [18]. These combined features result 
in plaque instability and vulnerability to rupture. As such, clinical detection of 
angiogenesis in vessel walls can be usedforthe assessment of plaque vulnerability. 
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lntegrin proteins play an important role in the course of angiogenesis. Importantly, 
avf33 integrin, a cell surface receptor which mediates adhesion of endothelial cells 
to extracellular matrix and migration of endothelial cells is crucial in the process 
of new vessel formation [6]. As such, avf33 integrin imaging can provide an 
invaluable tool to evaluate different pathological processes in which angiogenesis 
contribute to development of the disease, namely tumors and atherosclerosis. 
The RGD peptide sequence has shown high binding affinity for avf33 integrin and 
has been labeled with [ 1 8F] for molecular imaging on integrin in vivo [7]. 
In this study we showed that [ 1 8F]-RGD-KS micro PET imaging of CEA specimens is 
feasible. The uptake was heterogeneous along CEA specimens and differed plaque 
by plaque. The difference of uptake in different plaques raises the possibility that 
a proportion of surgically excised atherosclerotic plaques would have imposed 
lower risk of rupture according to [ 1 8F]-RGD-KS imaging. 
This research was designed according to a method developed by the department 
of Nuclear Medicine of our center for ex vivo imaging of carotid atherosclerotic 
plaques using a microPET camera system with a high spatial resolution [ 1 7]. 
The resolution of approximately 1 mm offers a unique opportunity to visualize 
atherosclerotic plaque in great detail to provide information on underlying 
processes within atherosclerotic plaque. The opportunity to visualize tracer 
accumulation within specimens with high resolution enabled us to compare 
tracer uptake in 4 mm segments of CEA specimens with immunohistochemical 
analysis of corresponding slides. 
A significant correlation was observed between [ 1 8F]-RGD-KS in each segment 
and immunohistochemical analysis of avf33 integrin, suggesting that [ 1 8F]­
RGD-KS enables us to visualize integrin presence and quantify integrin levels in 
human atherosclerotic plaques. Addition of excess unlabeled compound resulted 
in six times less [ 1 8F]-RGD-KS accumulation in samples and indicated avf33 
integrin-mediated tracer uptake. Good correlation of segmental-to-total ratio 
with CD31 staining score (p = 0.67, P = 0.002) was demonstrated in our study. CD31 
immunostaining was used as an endothelium-specific immunohistochemical 
marker as indicator of new vessel formation. The good correlation between 
segmental uptake in the lesion and intensity of CD31 staining suggests that [ 1 8F]­
RGD-KS imaging can indirectly assess angiogenesis, in addition to avf33 integrin. 
Moreover, a satisfactory hotspot-to-average ratio in [ 1 8F]-RGD-KS microPET 
images of CEA specimens makes [ 1 8F]-RGD-KS a promising tracer for future 
application for visualization of avf33 integrin expression in human arterial tissue 
to recognize lesions with a high target-to-background ratio. However, further 
studies need to be designed to determine optimal time point for blood clearance 
biodistribution of the tracer in non-target organs. 
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A previous study on [18F]-RGO-K5 imaging of xenograft tumor models reported a 
rapid blood clearance of the tracer which demonstrated a 2-hours post-injection 
specific uptake value = 0.05 - 0.15 percent injected dose per gram in plasma [13]. 
In a patient study on 9 individuals with malignant melanoma using [18F]-Galacto 
ROG the same pattern of rapid decline in blood activity was demonstrated within 
79 minutes after injection [1 O]. However, the specific uptake value of the tracer 
in blood in human study was higher than that of mouse model (1.17% injected 
dose per gram). In our study average %Inc/g of [18F]-RGO-K5 in hotspot (after one 
hour incubation) was 1.30% ± 0.34 (ranging from 0.65% to 1.93). This result shows 
the potential for in vivo application of [18F]-RGO-K5. However, the in vivo results 
of atherosclerotic plaque uptake and target-to-blood ratio in animal models and 
human subjects need to be experimentally determined. 
This study was the first to examine the feasibility of av�3 integrin ex vivo 
imaging in human atherosclerotic plaques. Molecular imaging of vulnerable 
plaques requires not only a highly-avid, target-specific probe and a high spatial 
resolution imaging modality, but also a deep understanding on predictive value 
of various underlying pathobiological processes in the course of disease. While 
inflammation, calcification, angiogenesis, and proteolysis have been suggested 
as major contributing processes leading to plaque instability, however these 
processes are overlapping and interactive pathways. Thus, it is not simple to 
describe a single process as main major underlying cause for plaque vulnerability 
to target for therapy and imaging. However, further research with ROG and other 
tracers leading to a combination of results may shed a brighter light on the 
presently enigmatic aspects of plaque vulnerability. 
Currently, different molecular imaging probes are being tested to reveal metabolic 
activity and macrophage infiltration [17, 19], VEGF abundance [20], and levels 
of matrix metalloproteinases [21] in experimental models of atherosclerosis. 
Moreover, [18F]-NaF PET imaging has shown the potential to depict micro­
calcifications in atherosclerotic disease and can be used for experimental models 
of vulnerable atherosclerotic plaques [22]. 
Molecular imaging of angiogenesis can provide a unique opportunity in 
monitoring progression and vulnerability of atherosclerotic plaques. In a previous 
study, we showed feasibility of imaging of VEGF abundance in CEA specimens 
using radiolabeled bevacizumab, targeted against VEGF. Although VEGF is known 
as a key regulator of angiogenesis, a recent study [23] showed that angiogenesis in 
atherosclerosis can occur through a VEGF-independent mechanism, as a result of 
oxidative stress through accumulation of the end products of lipid oxidation and 
integrin-mediated activation of toll-like receptors on endothelial cells. As such, 
molecular imaging of integrins targets an alternative pathway in angiogenesis in 
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atherosclerosis. Moreover, any molecular imaging technique on vulnerability of 
atherosclerotic plaque should address the correlation of tracer accumulation with 
not only the direct target and outcome but also to other key processes involved 
in atherosclerotic plaque progression and instability. Hence, future studies on 
[ 1 8F]-RGD-KS imaging should be designed to investigate implications of high 
[1 8F]-RGD-KS uptake on the outcome of atherosclerotic plaques. Additionally to 
integrins, the correlation between [1 8F]-RGD-KS accumulation with inflammation 
and proteolysis need to be determined. 
Conclusion 
This study demonstrated the potential of integrin imaging in determination of 
angiogenesis and vulnerability in atherosclerotic plaques. Non-invasive imaging 
and quantification of angiogenesis could provide clinicians a new tool in stratifying 
risk of cardiovascular events. 
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Minocycline, a second generation tetracycline antibiotic reduces cell death in 
animal models of myocardial infarction. Recently, visualization of secondary 
necrosis using lndium-1 1 1 -labeled 4-(N-(s-glutathionylacetyl) amino) 
phenylarsenoide (GSAO) was reported. As apoptosis blends into necrosis, we 
investigated the efficacy of minocycline as cell death inhibitor using GSAO 
imaging. 
Sixteen New Zealand White rabbits underwent 40 minutes of regional ischemia 
produced by coronary occlusion followed by 3 hours of reperfusion. The 
minocycline group (n = 8) received 30 milligram/kg of minocycline at the time 
of reperfusion intravenously; control group (n = 8) received saline. Radiolabeled 
GSAO was injected for non-invasive imaging using micro-SPECT/CT. Subsequently, 
hearts were explanted to acquire ex vivo images and measure the percent injected 
dose per gram (%IO/g) GSAO uptake, followed by histological and histochemical 
characterization. Myocardial damage was clearly visualized non-invasively by 
micro-SPECT imaging. The mean area at risk in control (0.337 ± 0.054%) and treated 
animals (0.320 ± 0.055%) was comparable (P=0.57, NS). The mean %IO/g GSAO 
uptake in the area at risk (AAR) was reduced 36% compared with control group 
(0.321 ± 0.1 1 3% VS 0.500 ± 0. 1 35%; P< 0.05). Histopathological characterization 
revealed a substantial decrease in myocardial damage. This study demonstrates 
the cardioprotective effect of minocycline with radiolabeled GSAO in ischemia/ 
reperfusion model. 
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Introduction 
Immediate reperfusion therapy, pharmacological and mechanical, constitutes the 
mainstay of management of patients presenting with acute myocardial infarction. 
The residual myocardial damage after reperfusion has a close linear relationship 
with the lapse of time from the onset of chest pain to the institution of reperfusion 
therapy [1 ]. As such, variable extent of myocardial damage is inevitable. Numerous 
cardioprotective agents have been investigated prior to introduction of 
reperfusion therapy with uncertain efficacy [2-5], but cardioprotective strategies 
have been infrequently employed to supplement reperfusion therapy. Although 
reperfusion therapy restores a large proportion of cardiomyocytes to normalcy 
(depending upon the time to intervention), a subset of cells suffers from oxidative 
reperfusion injury and is lost through the processes of accelerated apoptosis 
and secondary necrosis [6-8]. As such prevention of apoptotic spurt by caspase 
inhibition instituted before, at and after reperfusion has resulted in significant 
salvage of myocardial damage in experimental studies [9, 1 O]. Since apoptosis 
and necrosis comprise a continuum, the extent of myocardial protection by 
caspase inhibitors exceeds expectation [1 O] and even helps prevent evolution of 
myocardial remodeling and heart failure [11 ]. 
Since caspase inhibitors have not been used in clinical practice and long-term 
effects of their use are unclear, some cytoprotective agents (such as eniporide 
and minocycline) have been used in preliminary reports [12, 13]. Minocycline 
is a semi-synthetic derivative of tetracycline which is commonly used as an 
effective antibiotic agent. The cytoprotective properties of minocycline are well­
characterized in neurological disorders [14-16]. Several reports that minocycline 
may have cardioprotective effect against ischemia have also become available 
[13, 17, 18]. 
The extent of myocardial damage in acute ischemic insult, efficacy of reperfusion 
therapy and potential protective effects of various chemical interventions have 
been evaluated by radionuclide imaging for characterization of myocardial 
necrosis [19] and apoptosis [20, 21 ]. 
4-(N-(s-glutathionylacetyl)amino) phenylarsenoide (GSAO) is a trivalent arsenic 
peptide which exerts anti-tumor effect by inhibiting mitochondrial function in 
angiogenic endothelial cells [21 ]. GSAO specifically binds to molecules with 
dithiol moieties, most importantly Heat Shock Protein 90 (HSP90), which are 
abundant in the intracellular space, but extremely rare in the intracellular space. 
GSAO has recently been labeled with [111 In] and fluorescent probes to enable its 
use for molecular imaging. As labeled GSAO is membrane impermeable, GSAO 
targeting of its intracellular ligands requires membrane disruption and therefore 
demonstrates death of a necrotic phenotype. GSAO has been employed for 
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radionuclide imaging of response to chemotherapy in animal models of cancer 
[22] and to evaluate extent of myocardial damage [23] . These studies reported 
that GSAO accumulation demonstrated necrosis secondary to apoptotic signaling 
as GSAO-positive cells were Annexin AS-positive whereas vice-versa was not true 
and GSAO uptake correlated with TUN EL staining and [22, 23]. 
The present study was performed to evaluate the efficacy of minocycline, in an 
ischemia/reperfusion model, administered at the time of reperfusion to simulate 
the clinical situation; the extent of myocardial damage determined by non­
invasive imaging with gold-standard apoptosis tracer Annexin AS (AAS) and 
[111 ln]-labeled GSAO. 
Methods 
The protocol follows the Guidelines for the Care and Use of Laboratory Animals 
established by the National Institutes of Health (NIH Publication No. 85-23, revised 
1996) and has been approved by the Institutional Laboratory Animal Care and 
Use Committee at the University of California, Irvine. The study was performed in 
23 male New Zealand White rabbits (2.5 to 3.0 kg) receiving a standard diet and 
water, obtained from Western Oregon Breeding laboratories (Philomath, OR). 
Experimental myocardial infarction, treatment and radionuclide administration 
Experimental acute myocardial ischemia/reperfusion model was studied as 
described previously [24]. Briefly, all rabbits were anesthetized with a mixture 
of ketamine and xylazine (0.5 to 0.6 mg/kg administered subcutaneously, 10:1 
vol/vol mixture of 100 mg/ml each). Surgical tracheostomy was performed, and 
ventilation was maintained with a Harvard rodent positive-pressure respirator 
(Harvard Apparatus Co., Inc., S. Natick, MA.). Anesthesia was maintained with 
1.0-5.0% of isoftuorane inhalation. The heart was exposed through a parasternal 
thoracotomy. The pericardium was removed. The region of the Left coronary artery 
(LCA) was identified between the aortic root and the left auricle. A monofilament 
suture was placed on the lateral branch of LCA, which was occluded by tightening 
the snare created by passing the suture through a polyethylene tubing. 
Coronary occlusion was confirmed by the elevation of ST segment on continuously 
monitored-electrocardiogram and the cyanotic change over the surface of heart 
in the territory perfused by occluded vessel. Forty minutes after occlusion, the 
snare was loosened to institute reperfusion. Right before reperfusion, the animals 
randomly received either minocycline hydrochloride (Sigma-Aldrich, St. Louis, 
MO) (30 milligram/kg, n=l 2) or 0.9% saline (n= l 1) injected through the marginal 
ear vein (Figure 1 ). At thirty minutes after onset of reperfusion, animals received 
either GSAO (8 minocycline treated and 8 saline treated) or AAS (4 minocycline 
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treated and 3 saline treated). At three hours after GSAO or AAS administration, 
respectively animals underwent in vivo SPECT/CT imaging. Thereafter, the animals 
were sacrificed using an overdose of sodium pentobarbital ( 1 20 mg/kg), hearts 
were explanted and ex vivo SPECT/CT, and static imaging and gamma-counting 
of the hearts was performed. 
GSAO and radio/abeling 
The GSAO used for imaging in the present study was provided by Covidien (St. 
Louis, MO); the structure of DTPA-GSAO was reported previously [22]. To bind 
[ 1 1 1  In] to the DTPA-GSAO conjugate, DTPA-GSAO (9.2 µg) was dissolved in 95 µL 
of 0.9% sterile saline and then added to buffer (36 µL; 0.5 mmol/L sodium acetate, 
trihydrate and 0.25 mmol/L ascorbic acid) and 200 µI of [ 1 1 1  ln]-Cl3. The mixture 
was incubated at room temperature for 1 5  minutes. Radiolabeling was confirmed 
by instant chromatography with radio-purity of more than 99%. For nuclear 
imaging, 1 8.3± 2.5 MBq of [1 1 1  ln]-GSAO was intravenously administered to all 
animals through the marginal ear vein 30 minutes after reperfusion. 
AAS and radio/abeling 
The AAS used for the current study was provided by Theseus Imaging Corp 
(Cambridge MA). The development as well as application of the human 
recombinant Hynic-AAS have been previously reported [25]. Shortly, 1 00 µg 
of human recombinant Hynic-AAS was mixed with ca. 740 MBq pertechnetate 
(1 ml). Subsequently, 0.1 ml stannous tricine buffer was added to the vial for 
pertechnetate reduction. This mixture was allowed to incubate (30 min, r.t.). The 
pH was measured (limits pH 5-7) and radiochemical purity (RCP) was assessed 
by TLC on silica impregnated paper (Gelman Sciences, Ann Arbor, Ml) using ACD 
buffer as the eluent. This method showed that the radiolabeling protocol yielded 
a radiochemical purity of 91 .3 ± 4.3%. 
In vivo and ex vivo imaging protocols 
Imaging was performed using a dual-head micro-SPECT gamma camera 
combined with micro-CT (X-SPECT, Gamma Medica, Inc., Northridge, CA) with 
the same imaging protocol. For in vivo imaging, the anesthetized animals was 
fixed on the bed of the scanner and mechanically ventilated. For ex vivo imaging, 
the explanted heart was put on the bed. mages of the heart was acquired in a 
64 x 64 matrix, 32 stops at 30 seconds per stop at 247 keV photopeak of [ 1 1 1  In] 
with 1 5% windows using a medium energy parallel-hole collimator for GSAO 
imaging and at 1 40 KeV photopeak of [99mTc] with 1 5% windows using a low 
energy parallel hole collimator for the ex vivo AAS scans. Immediately after SPECT 
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imaging, a micro-CT scan was acquired using an X-ray tube operating at 50 kVp 
and 0.8mA. Images were captured for 2.5 seconds per view for 256 views in a 
360°rotation. After transferring to 256 x 256 matrix, the micro-SPECT images and 
micro-CT tomographic studies were fused, allowing scintigraphic and anatomic 
in all tomographic scans in the 3 different spatial axes. 
After ex vivo SPECT/CT imaging, the heart was cut into 4 equidistant slices from 
apex to base. In all cases, the coronary suture was located in 4th slice. Then the 
slices were cut into a total of 32 pieces as per standard protocol. Subsequently, 
all pieces were weighed, and gamma counted in an automatic well type gamma 
counter (PerkinElmer Wallac, Inc., Gaithersburg, MA) for calculation of the percent 
injected dose per gram (%ID/g) uptake in heart tissue. The myocardial pieces of 
animals imaged with GSAO were then preserved for histological and histochemical 
investigation. Tissue samples of the main organs were used for calculation of the 
%ID/g uptake to evaluate the biodistribution. To correct for the radioactive decay 
and permit calculation of the concentration of radioactivity as a fraction of the 
administered dose, aliquots of the injected dose were counted simultaneously. 
To evaluate radionuclide uptake in infarcted and remote areas, the uptake of the 
sections constituting the tertiles (by weight) with the highest and the lowest 
uptake were compared. To exclude uptake identifying mechanical damage due 
to the coronary suture, slice four was removed from the analysis. 
Histological study 
The heart specimens were fixed overnight with 4% paraformaldehyde in 
phosphate-buffered saline, pH 7.4, at 4°C, and stored in phosphate-buffered 
saline with 0.02% sodium azide at 4°C. The fixed tissue specimens were paraffin 
embedded, and 4-µm thick section were obtained. For histological comparison, 
tissue sections from remote area and area at risk were selected. The tissue sections 
were then deparaffinized for histologic assessment and the sections were stained 
with Hematoxylin & Eosin. The presence of apoptotic cells was evaluated by 
histologic detection of DNA fragmentation by terminal deoxyribonucleotide 
transferase TdT-mediated nick-end label (TUN EL) staining using an in situ apoptosis 
detection kit (TACS, Trevigen, Inc., Gaithersburg, MD) as described previously 
[26]. Stained tissue sections were observed under appropriate magnification 
(Zeiss Axivert-200 microscope, Carl Zeiss, Inc., Thornwood, NY), and images were 
captured with a high resolution digital camera (Axiocam, 1,300 x 1 ,030 pixels, Carl 
Zeiss) using Axivision 3. 1 software. 
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Statistical analyses 
Data are expressed as means ± SD. Statistical analysis was performed by the one­
way analysis of variance. If F test results were <0.05, Student-Newman-Keuls test 
post hoc test was performed. A value of p<0.05 was considered significant. 
Results 
Imaging and quantification of GSAO uptake in ischemia-reperfused heart In vivo 
micro-SPECT/ micro-CT with [111 ln]-GSAO allowed non-invasive visualization of 
myocardial necrosis. Intense GSAO uptake was observed in the infarcted area in 
both control and minocycline treated animals. The intensity and area of GSAO 
uptake were markedly reduced in the group of animals treated with minocycline 
than in that of untreated animals. No uptake was observed in the remote area in 
both groups. (Figure 1 a). The ex vivo images of the explanted heart confirmed the 
in vivo distribution of [111 ln]-GSAO (Figure 1 b). 
While proportion of AAR in ventricular tissue of treated and untreated animals 
did not differ significantly; gamma-counting confirmed lower GSAO uptake 
in minocycline-treated group (0. 32 ± 0.11 %) compared with the untreated 
group (0.50 ± 0.13%; p<0.05) (Figure 2b), this confirmed a 36% lower uptake in 
minocycline treated group. GSAO uptake in remote area of minocycline treated 










Figure 1. (a) In vivo and (b) ex vivo SPECT and SPECTICT images, (c) ex vivo static images and (d) 
quantitation by g-counting of minocycline treated and control groups in ischemia-reperfusion model 
reveal significantly reduced GSAO uptake in minocycline treated group. 
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Figure 2. Percentage of AAR per ventricular tissue (a) and gamma-counting results of GSAO uptake in 
AAR and remote left ventricular tissue in minocycline- treated and control mice (b). 
AAR = area at risk; GSAO = 4-(N-(s-glutathionylacetyl)amino) phenylarsenoide 
Imaging and quantification of AAS uptake in ischemia-reperfused heart Ex vivo 
micro-SPECT/micro-CT with [99mTc]-AAS demonstrated significantly higher AAS 
uptake in the infarcted area in both control and minocycline treated animals, as 
compared to remote non-infarcted areas; the intensity and area of AAS uptake 
was markedly lower in the group of animals treated with minocycline compared 
with untreated animals (data not shown). The ex vivo images of the explanted 
heart confirmed the in vivo cardiac distribution of[111 ln]-GSAO (Figure 1 b). No 
uptake was observed in the remote area in both groups. 
Histopathologic assessment 
Hematoxylin staining demonstrated the myocardial changes including 
hypereosinophilic myocytes. These changes were qualitatively minimized in 
the minocycline-treated animals (Figure 3a). The TUNEL-positive cells were 
significantly fewer in minocycline group compared with untreated group both 
in the area at risk (0.2S ± 0.20 vs 2.28 ± 1.39, P<0.0S) (Figure 3b). There was no 
difference in remote area in the number of TUNEL+ cells (0.037 ± 0.036 vs 0.02 ± 
0.003)(Figure 3b). GSAO uptake showed a weak (but significant) direct correlation 
with TUNEL+ cells (Figure 3c). 
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Figure 3. (a) Histopathological characterization of treated and control animals. Hematoxylin & eosin 
(H&E) staining, and TUN EL staining (apoptosis) reveal significantly higher myocardial damage and 
apoptosis in area at risk in minocyc/ine treated animals when compared with control animals. Remote 
areas have similar morphology. (b) Quantitative analysis of TUN EL staining confirms significantly lower 
apoptosis in area at risk of minocycline treated animals when compared to control animal. 
(c) A signifant correlation between TUN EL positivity and GSAO uptake was observed. 
Discussion 
Energy depletion during ischemia and production of radical oxygen species and 
calcium overloading during reperfusion trigger transition of apoptosis to cell 
death of a necrotic phenotype which is characterized by membrane disruption [7, 
26, 27]. Thus, apoptosis and necrosis operate on a spectrum, and the protective 
effects of anti-apoptotic strategy far exceed those expected from resolution 
of apoptosis alone [1 O]. For this reason, while previous studies mainly focused 
on anti-apoptotic effects of minocycline, we decided to evaluate the effects of 
minocycline intervention on apoptosis using AAS and secondary necrosis using 
GSAO. 
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We demonstrated minocycline-induced reduction of the apoptosis-necrosis 
spectrum as depicted by AAS imaging, TUNEL Staining and GSAO imaging. This 
was further supported by the correlation between GSAO uptake and TUNEL 
staining. Probably, several cytoprotective effects of minocycline are responsible 
for this. In animal models of myocardial infarction minocycline has been shown 
to directly reduce apoptosis through inhibition of pro-apoptotic markers such 
as Poly ADP-Ribose Polymerase (PARP) [28] caspases [13], Smac/Diablo [13] and 
upregulation of anti-apoptotic molecules such as XIAP[13]. Further inhibition 
of apoptotic signaling and its transition to necrosis is probably derived from 
direct antioxidant [17] and anti-inflammatory [17, 18] effects and mitochondrial 
stabilization [29]. 
Regardless of the mechanism of intervention, it seems advisable that we use 
all in our armamentarium to restrict myocardial damage [6] and minimize the 
morbidity and modality associated with myocardial infarction. 
76 I Chapter 4 
Conclusions 
The present study shows minocycline reduced the extent of myocardial damage 
in ischemia/reperfusion model determined by non-invasive imaging with AAS 
and [111 ln]-labeled GSAO. If verified in clinical trials, this antimicrobial agent can 
be used to supplement reperfusion therapy in clinical practice. This study also 
confirms the cross-talk between various forms of cell death and that intervention 
at any stage may yield disproportionately superior outcomes. 
77 
Reference List 
1 .  Giugl iano RP, Braunwald E. Selecting the best reperfusion strategy i n  ST-elevation myocardial 
infarction: it's all a matter of time. Ci rcu lation 2003 Dec 9; 1 08(23):2828-30 
2. Peter T, Norris RM, Clarke ED, et al. Reduction of enzyme levels by propranolol after acute 
myocardial i nfarction. Circulation 1 978 Jun;57(6) : 1 091 -5 
3. Kloner RA, Reimer KA, Wil lerson JT, et al. Reduction of experimental myocardial infarct size 
with hyperosmolar mannitol .  Proc Soc Exp Biol  Med 1 976 Apr; l 5 1  (4):677-83 
4. Libby P, Maroko PR, Bloor CM, et al. Reduction of experimental myocardial infarct size by 
corticosteroid admin istration. J Cl in  Invest 1 973 Mar;52(3):599-607 
5.  Maroko PR, L ibby P, Sobel BE,  et al .  Effect of g lucose-insu l in-potassium infusion on myocard ial 
i nfarction fol lowing experimental coronary artery occlusion. Circu lation 1 972 Jun;45(6) : 1 1 60-
75 
6. Naru la J, Baliga R. What's in a name? Would that which we cal l  death by any other name be 
less tragic? Ann Thorac Surg 2001 Nov;72(5) : 1 454-6 
7. Naru la J, Strauss HW. I nvited commentary: P.S.* I love you:  impl ications of phosphatidyl serine 
(PS) reversal in acute ischemic syndromes. J N ucl Med 2003;44(3):397-9 
8. ltoh G, Tamura J, Suzuki M, et al .  DNA fragmentation of human infarcted myocardial cel ls 
demonstrated by the nick end label ing method and DNA agarose gel electrophoresis. Am J 
Pathol 1 995 Jun;l  46(6) : 1 325-3 1 
9. Dumont EA, Reutel ingsperger CP, Smits JF, et al .  Real-time imaging of apoptotic cel l­
membrane changes at the s ing le-cel l  level in  the beating murine heart. Nat Med 
2001 ;7(1 2) : 1 352-5 
1 0. Yaoita H, Ogawa K, Mae hara K, et al .  Attenuation of ischemia/reperfusion injury in rats by a 
caspase inhibitor. Circu lation 1 998 Jan 27;97(3) :276-8 1 
1 1 . Chandrashekhar Y, Sen S, Anway R, et al .  Long-term caspase inhibition amel iorates apoptosis, 
reduces myocardial troponin-I cleavage, protects left ventricu lar function, and attenuates 
remodeling in rats with myocardial infarction. J Am Col l  Cardiol 2004 Jan 2 1 ;43 (2):295-301 
1 2. Dumont EA, Hofstra L ,  van Heerde WL, et al .  Cardiomyocyte death induced by myocardial 
ischemia and reperfusion: measurement with recom binant human Annexin-V in a mouse 
model. Circu lation  2000 Sep 26; 1 02( 1 3) : 1 564-8 
1 3. Scarabel l i  TM, Stephanou A, Pasin i  E, et al. Minocycl ine inhibits caspase activation and 
reactivation, increases the ratio of XIAP to smac/DIABLO, and red uces the mitochondrial 
leakage of cytochrome C and smac/DIABLO. J Am Col l  Cardiel 2004;43 (5):865-74 
1 4. Yrjanheikki J, Keinanen R, Pel l ikka M, et al .  Tetracycl ines inhibit microg l ial activation and are 
neuroprotective in g lobal brain ischemia. Proc Natl Acad Sci U S  A 1 998;95(26) :1 5769-74 
1 5. Zhu S, Stavrovskaya IG, Drozda M, et al. M inocycl ine i nhibits cytochrome c release and delays 
progression of amyotrophic lateral sclerosis in mice. Nature 2002;4 1 7(6884):74-8 
1 6. Lampl Y, Boaz M, Gi lad R, et al. Minocycl ine treatment in acute stroke: an open-label, 
evaluator-bl inded study. Neurology 2007;69( 1 4) : 1 404- 1 0 
1 7. Romero-Perez D, Fricovsky E, Yamazaki KG, et al .  Cardiac uptake of minocycl ine and 
mechanisms for i n  vivo cardioprotection. J Am Col l  Card iel 2008;52 ( 1 3) :l  086-94 
1 8. Hu X, Zhou X, He B, et al. Minocycl ine protects against myocard ial ischemia and reperfusion 
injury by inhibiting high mobi l ity group box 1 protein in  rats. European journal of 
pharmacology 201 0;638(1 -3):84-9 
1 9. Naru la J, N icol P D, Southern JF, et al. Evaluation of myocardial i nfarct size before and 
after reperfusion: dual-tracer imaging with rad iolabeled antimyosin antibody. J Nucl Med 
1 994;35 (6) : 1 076-85 
20. Hofstra L, Liem I H, Dumont EA, et al. Visualisation of cel l death in vivo in patients with acute 
myocardial i nfarction.  Lancet 2000 Jul 1 5;356(9225) :209-1 2  
78 I Chapter 4 
2 1 .  Kenis H, Zandbergen HR, Hofstra L, et al . Annexin AS uptake in ischemic myocardium: 
demonstration of reversible phosphatidylserine external ization and feasibi l ity of radionucl ide 
imaging. J Nucl Med 201 0;5 1 (2):259-67 
22. Park D, Don AS, Massamiri T, et al. Noninvasive imaging of cel l death using an Hsp90 l igand. J 
Am Chem Soc 201 1 Mar 9; 1 33 (9):2832-5 
23. Tahara N. Noninvasive Molecular Imaging of Cell Death in Myocardial I nfarction by Targeting 
of  Intracel lu lar HSP-90. 201 3. Manuscript submitted for publ ication 
24. Narula J, Petrov A, Pak KY, et al. Very early noninvasive detection of acute experimenta l 
nonreperfused myocard ial infarction with [99mTc]-labeled glucarate. Circulation 1 997 Mar  
1 8;95(6) : 1 577-84 
25. Ohtsuki K, Akashi K, Aoka Y, et a l. Technetium-99m HYNIC-Annexin V: a potential 
radiopharmaceutical for the in-vivo detection of apoptosis. Eur J Nucl Med and Mol Imaging 
1 999; 26: 1 25 1 -8 
26. Ha lestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeabil ity transition pore opening 
during myocardial reperfusion--a target for cardioprotection. Cardiovasc Res 2004 Feb 
;61 (3):372-85 
27. Kim JS, He L, Lemasters JJ. Mitochondrial permeabil ity transition: a common pathway to 
necrosis and apoptosis. Biochem Biophys Res Commun 2003;304(3):463-70 
28. Tao R, Kim SH, Honbo N, et al. Minocycl ine protects cardiac myocytes against simulated 
ischemia/reperfusion injury by inh ibiting poly(ADP-ribose) polymerase- 1 .  J Card iovasc 
Pharmacol 201 0 Dec;56(6):659-68 
29. Sloan RC, Moukdar F, Frasier CR, et al. Mitochondrial permeabil ity transition in the diabetic 
heart: contributions of thiol redox state and mitochondrial ca lcium to augmented reperfusion 
injury. J Mol Cel l Cardiol 201 2  May;52(5) : 1 009-1 8 
79 
Chapter 
80 I Chapter 5 
Abdominal aortic calcification detected by dual x-ray absorptiometry: a 
strong predictor for cardiovascular events 
Reza Golestani 1 , Rene A. Tio2•6, ClarkJ. Zeebregts3•6, Aafke Zei lstra 1 , Rudi A. Dierckx 1 , 
Hendrikus H. Boersma 1A•6, Hans L. H i l lege5, Riemer H .J.A. S lart1 •6 
1 Department of Nuclear Medicine and Molecu lar Imaging, 2Thorax Center, 
Department of Cardiology, 3Department of Surgery, Division of Vascular Surgery, 
4Department of C l in ical Pharmacy, 5Department of Epidemiology, 6Cardiovascu lar 
Imaging Group Gron ingen, University Medical Center Gron ingen (UMCG}, 
University of Gron ingen, the Netherlands. 
Annals of Medicine. 20 1 O; 42: 539-545. 
81  
Abstract 
Background- Vertebral fracture assessment (VFA) using dual-energy X-ray 
absorptiometry (DEXA) can visualize abdominal aortic calcification (AAC). AAC is 
shown to be correlated with total atherosclerosis burden. We questioned whether 
VFA detected AAC could be used for cardiovascular risk assessment. 
Methods - VFA images of 2500 subjects were evaluated to detect and score AAC 
(n= l 64). A random age- and gender-matched set of subjects (n = 325) without AAC 
served as control group. Patients with prior cardiovascular disease or procedures 
were excluded. Baseline cardiovascular risk factors and further cardiovascular 
events were checked. Design based Cox regression analysis was used to examine 
the prognostic value of AAC for cardiovascular outcomes. 
Results- AAC-positive subjects were divided into two groups: low-AAC (score 1-3), 
and high-AAC group (score > 3). Mean age in the groups was 68 ± 9, 68± 9, and 71 ± 
11 yrs in control, low-AAC, and high-AAC groups, respectively, and the percentage 
female was 64.4%, 61 %, and 66.1 %. The proportion of total cardiovascular events 
within each group was 1.5%, 6.7%, and 11.9% for control, low-AAC and high-AAC 
groups, respectively. Age- and gender-adjusted, as well as multi-variable analysis 
showed a significant higher risk for cardiovascular events incidence in AAC­
positive, low-AAC, and high-AAC when compared to the control group. 
Interpretation- AA( assessed with routine VFA was shown to be a strong predictor 
for cardiovascular events. 
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Introduction 
Atherosclerosis can be considered as a systemic disease capable of affecting 
all arteries in the body. Calcification of atherosclerotic plaques has been well 
recognized as risk indicator. It is known that the burden of aortic calcification 
correlates with the degree of atherosclerosis in other arteries [1,2]. Many studies 
have shown that abdominal aortic calcification (AAC) detected by either lateral 
lumbar spine radiographs or CT scan is an independent predictor for cardiovascular 
disease (CVD) incidence and mortality [3-1 1]. AAC assessment with conventional 
radiologic techniques has the disadvantage of relative high radiation burden 
(1.5 mSv in lateral spinal x-ray [ 1 2]) and is thus less desirable for physicians and 
patients as screening tool. 
Dual energy x-ray absorptiometry (DEXA) is a standard diagnostic technique 
widely used to detect osteoporosis [ 1 3] and vertebral fractures (the hall mark of 
osteoporosis [14]) with minimal time, and radiation exposure [ 1 5, 1 6]. In 2002 in the 
USA a total 2, 1 95,548 DEXA scans were performed among all Medicare patients 
[1 7]. Osteoporosis and atherosclerosis have many risk factors in common, such 
as body mass index, smoking, age, physical activity, and (treatment for) diabetes 
mellitus. In addition, the coexistence of risk factors for atherosclerosis and 
osteoporosis in healthy women has been recently reported [18]. It may therefore 
be prudent to evaluate the cardiovascular risk in patients at risk for osteoporosis. 
Vertebral fracture assessment (VFA) and bone densitometry images intended 
to detect osteoporosis match reliably with lateral spine radiography results, 
accompanied by a very low radiation dose of less than 0.01 mSv [ 1 9,20]. In this 
context it is a beneficial coincidence that VFA images using DEXA technique can 
reveal AAC with good sensitivity and specificity compared to standard lateral spine 
radiographs [19,21,22]. However, the relationship between elevated AAC using 
VFA and risk for the occurrence of cardiovascular events are not well surveyed. A 
previous study evaluated the association of AAC scored on VFA images in patients 
with myocardial infarctions or stroke in elderly women [23], because DEXA studies 
are mainly performed in women. Studies that are focused on the direct risk of 
cardiovascular events in men and women related to AAC are lacking. Thus routine 
application of AAC analysis in patients referred for bone mineral densitometry 
(BMD) and VFA could provide clinicians an opportunity for cardiovascular risk 
stratification. The aim of this study is to investigate the prognostic value of AAC in 
cardiovascular events in men and women using routine VFA images. 
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Materials and Methods 
Patients 
All consecutive patients referred for BMD between 2005 and 2007 were examined 
for AAC by two independent physicians blinded for patients' medical history. The 
population comprised patients who were tested for BMD at University Medical 
Center Groningen (UMCG), the Netherlands. Subjects with positive abdominal 
aortic calcification were identified. A 1 :2 age- and sex-matched set of subjects with 
negative abdominal aortic calcification were chosen as a control group. Patients 
lacking sufficient information on outcome and risk factors were excluded. This 
study was approved by the Institutional Ethics Review Board. 
Study and AAC scoring procedure 
Lateral single-energy images (VFA images) of the lumbar spine were obtained on 
a Hologic Discovery A densitometer (Hologic, Inc., Bedford, MA, USA). While the 
patient remained in a supine position the C-arm of the machine moved to the 
lateral position and then a lateral fan-beam -ray image of the spine was obtained. 
Images that could not be used due to mis-positioning of the aorta in the field 
were not used for analysis (n = 266; 10.6%). To quantify calcification burden in the 
abdominal aorta, we applied eight-score scale system [21 ]. This scale estimates the 
total length of calcification on the anterior and posterior aortic walls separately 
in the region anterior to the L 1-L4 vertebral bones. In this scale, 0 stands for no 
calcification, one for aggregate length of calcification up to height of one vertebra, 
two for aggregate length of calcification between one and two vertebrae, three 
for aggregate length of calcification between two and three vertebrae and four 
for more aggregate length in each of the anterior and posterior aortic walls. Total 
score was the summation of anterior and posterior calcification scores and ranged 
from zero to eight (figure 1 ). 
In order to validate VFA images for AAC assessment, 53 patients that underwent 
VFA as well conventional lateral X-ray of the spine because of suspected vertebral 
fracture were selected and compared blinded by an expert reader (figure 1 ). 
Cardiovascular risk factors and outcome 
Our medical center maintains a computerized information system of all patients 
admitted to the hospital. We checked the information system for relevant medical 
history at the time of the DEXA scan. Subjects with a history of angina pectoris, Ml, 
CVA, or TIA or past invasive procedure for cardiovascular diseases were excluded 
from the study. Relevant medical history and family history of cardiovascular 
diseases (premature coronary heart disease, Ml, CVA, or TIA) in first degree relatives 
were included according to medical file of the patients on the hospital information 
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system prior to DEXA imaging at the date nearest date of VFA. Hypertension was 
defined as blood pressure 2:: 140/90 mmHg, current antihypertensive medication 
including diuretics, or family physician's note. Hypercholesterolemia was defined 
as total cholesterol levels > 200 mg/dl, current use of lipid lowering agents, or 
family physician's note. A fasting plasma glucose level 2:: 1 26 mg/dl or the use 
of anti-diabetic medications was considered as diabetes mellitus. Subjects who 
smoked 2:: one cigarette per day within one year prior to VFA were considered 
as smoker. Non-fatal-Ml, -CVA, and TIA, were ascertained according to ECG, 
troponin and creatine kinase (CK MB) levels, available CT scan, or physician note 
on patient's file and evaluated by two study experts, blinded to the individuals' 
AAC scores. Cardiovascular death was ascertained if a fatal-MI/-CVA occurred in 
individuals without known atherosclerotic disease. The patients who did not have 
an updated medical report on any of risk factors or outcomes were excluded from 
the study (n = 1 2; 3 patients in the AAC-positive group and 9 patients in AAC­
negative group. The latter were replaced by age- and gender-matched subjects). 
Figure 1. An example of severe AAC (score 8) with conventional X-ray (A) compared with VFA DEXA (BJ. 
Statistical analysis 
All subjects with detectable calcification on VFA were identified. An age- and sex­
matched control group was selected in a 2: 1 ratio (2 controls for each case). Survival 
was estimated by the Kaplan-Meier product-limit method, compared with the log­
rank test, and stratified for the three groups. Subjects with calcification burden 
were over-selected to acquire sufficient subjects with AAC. To overcome this over 
sampling of subjects with AAC a design-based analysis was performed. Due to 
this weighing method our conclusions can be generalized for the original cohort 
of consecutive patients who underwent VFA. The design-based Cox proportional-
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hazards regression models evaluating the prognostic properties of AAC to the risk 
of CV events were built with STATA (STATA, Texas version 10.0). To correct for within­
pair correlation of observations among subjects, we applied cluster specification 
to obtain robust estimates of variance as described previously [24]. Data was 
expressed as mean ± standard deviation (SD). Results are summarized by hazard 
(risk) ratios with 95% confidence intervals (95% Cl). Baseline characteristics were 
compared within groups using chi-square for categorical variables and student's 
t-test for continuous variables. Weighted Kappa statistics were used to assess 
agreement in AAC scoring between VFA and conventional lateral spine X-ray. All 
reported probability values are 2-tailed and P < 0.05 was considered statistically 
significant. 
Results 
Two thousand and five hundred consecutive patients (mean age ± SD: 52 ± 15; 
65% female) underwent VFA imaging between 2005 and 2007. One-hundred­
sixty-seven (6.6%) had detectable calcification, and they were divided according 
to AAC score into two groups, low-AAC (1-3; n = 108, of whom three subjects 
were excluded later due to lack of information) and high-AAC (4-8; n = 59). Three 
hundred and twenty five subjects without calcification served as age- and sex­
matched control group. The baseline characteristics of 489 subjects according to 
AAC status are shown in table 1. Statistically significant differences were observed 
in percentage of cardiovascular risk factors within different groups. Moreover, 
despite the age-matched control group formation, mean age in the high-AAC 
group was significantly higher than the control group. 
Subjects were followed up for cardiovascular events for 2-60 months (median 
31 months). The total number of cardiovascular events was 19. Among the 325 
subjects in the control group, five subjects had a cardiovascular event. Seven 
cardiovascular events in the low-AAC group and another 7 cardiovascular events 
in the high-AAC group were observed. The incidence of non-fatal cardiovascular 
events was 5 (1.5%), 5 (4.8%), and 7 (11 .9%) in control, low-AAC, and high-AAC 
groups, respectively. Ml and CVA/TIA incidences among different groups are 
shown in table 2. Cumulative event rate for total cardiovascular events during the 
follow-up period was 1 .5%, 6.7%, and 11 .9% for control, low-AAC and high-AAC 
groups, respectively (figure 2). 
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Control Low-AAC 
n=325 n=105 
Mean age ± SD (yrs) 68 ± 9  68 ± 9  
Female {%) 210(64.4%) 64(61.0%) 
Hypertension {%) 98(30.2%) 51(48.6%)* 
Hypercholesterolemia (%) 53(16.3%) 30(28.6%)* 
OM (%) 35(10.8%) 22(21.0%)* 
Smoking (%) 38(11.8%) 38(36.2%)* 
Family history(%) 21(6.5%) 15(14.3%)* 
Table 1. Base-line characteristics of study population. 
* P value < 0.05 compared with the control group. 
High-AAC Total AAC positive 
n=59 N=164 
71 ± 11* 69± 10 
39(66.1%) 103 {62.8%) 
36(61.0%)* 87 (53%)* 
18(30.5%)* 48 (29.3%)* 
9(15.5%) 31 (19%)* 
16(27.6%)" 54 (33.1%)* 
12(20.7%)* 27 (16.6%)* 
SD = standard deviation; OM = diabetes mellitus; AAC = abdominal aortic calcifation. 
In the Cox proportional hazard model, it was confirmed that AAC is associated 
with higher cardiovascular hazard risk, independent of age, sex, and conventional 
cardiovascular risk factors, as shown in table 4. 
The Cox proportional hazard model showed that in comparison with the control 
group the AAC score was also associated with a higher risk of ca rd iovascu la r events. 
A significantly higher hazard ratio (HR) was found in both the low-AAC (HR: 4.7; Cl 
95%: 1.5 - 15.2; p = 0.009) and the high-AAC groups (HR: 8.6; Cl 95%: 2.7 -27.1; p< 
0.0001) (table 3). Adjusted analysis showed that this association was independent 
of age and sex in both low-AAC (HR: 4.9; Cl 95%: 1.5-15.9; p = 0.008) and high-AAC 
groups (HR: 7.3; Cl 95%:2.2-23.9; p = 0.001 ). After the addition of conventional 
cardiovascular risk factors, the model still showed significant predictive value in 
both low-AAC (HR: 4.2; Cl 95%: 1.2-15.4; p = 0.027) and high-AAC groups (HR: 6.1; 
Cl 95%: 1.7-21.6; p = 0.005) compared with the control group (table 3). 
AAC score in a sub-selection of 53 patients that underwent VFA as well as 
conventional lateral X-ray of spine were compared by an experienced physician 
blind to the results of other modality, statistical analysis showed excellent 
agreement with a Kappa of 0.87 (Cl 95%: 0.66-1 ). 
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Control group 325 321 308 122 
Low-AAC 105 101 75 20 
High-MC 59 54 44 12 
Figure 2. Kaplan-Meier curve for cumulative event-free survival in each group and population at risk at 
each time point. 
Control Low-AAC High-AAC 
Group 
CVA/TIA (%) 2(0.6%) 2(1.9%) 3(5.1%) 
Ml (%) 3(0.9%) 4(3.8%) 4(6.8%) 
Total individuals with non-fatal events (%) 5(1.5%) 5 (4.8%) 7(11.9%) 
Total individuals with cardiovascular events (%) 5(1.2%) 7(6.7%) 7(11.9%) 
Table 2. Number and percentage of cardiovascular events in relation to AAC. 
CVA = cerebrovascular accident; TIA = transient ischemic attack; Ml = myocaridal infarction. 
Control Low-AAC High-AAC 
n = 325 n = 105 n = 59 
Univariate analysis 1.0 4.7( 1.5 - 15.2) 8.6(2.7 -27.1) 
p < 0.01 p< 0.0001 
Gender-, age-adjusted 1.0 4.9 ( 1.5-15.9) 7.3(2.2-23.9) 
p =  0.008 p = 0.001 
Multivariate-adjusted 1.0 4.2( 1.2-15.4) 6.1(1.7-21.6) 
p =  0.027 p = 0.005 
Table 3. Cox regression analysis for comparing control, low-AAC, and high-AAC groups. Univariate, 
gender- and age-adjusted, and multivariate-adjusted hazard ratio for AAC in cardiovascular events 
(95% confidence interval). Control group served as reference. Multivariate analysis involved: age, 
gender, hypertension, hypercholesterolemia, diabetes mellitus, smoking, and family history of coronary 
heart disease. 
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Discussion 
In this study we showed the predictive value of AAC on DEXA scans which 
were performed for routine clinical evaluation of VFA. The strong, independent 
association between cardiovascular events rate and AAC level gives an opportunity 
to physicians for early risk stratification of cardiovascular diseases in subjects 
referred for BMD and VFA. A hazard rate of 1 1 .9% (HR: 6.4) in the AAC-high group 
implies the need for more thorough diagnostic efforts in these subjects. Univariate analysis Gender-, age-adjusted Multivariate-adjusted Control group n = 325 1.0 1.0 1.0 MC-positive n = 164 6.13 (2.20 - 17.05) p = 0.000 6.01 (2.15 - 16.79) p = 0.001 5.35 (1.85- 15.45) 
p = 0.002 
Table 4. Cox regression analysis for comparing AAC-negative versus AAC-positive subjects. Univariate, 
gender- and age-adjusted, and multivariate-adjusted hazard ratio for AAC in cardiovascular events 
(95% confidence interval). Control group served as reference. Multivariate analysis involved: age, 
gender, hypertension, hypercholesterolemia, diabetes mellitus, smoking, and family history of coronary 
heart disease. 
Abdominal aortic calcification detected by lateral spinal radiography and CT scan 
has previously been shown to be an independent predictor of cardiovascular 
diseases [3- 1 1 ]. It is noteworthy that DEXA is able to accurately measure AAC 
level in comparison with lateral spinal radiographs [ 1 9,2 1 ] and assess vertebral 
fractures [ 1 4, 1 6] with less radiation, lower costs and in less time [5, 1 9-2 1 ]  with a 
good intra-rater variability [ 1 9]. 
Interestingly, DEXA is able to assess total and regional body fat mass composition 
[25-27], which has been reported to be associated with cardiovascular risk 
factors [28-31 ]. According to recommendations for osteoporosis screening, bone 
densitometry and simultaneous lateral spine imaging for VFA should be performed 
in a notable subset of elder population [ 1 3, 1 5, 1 6]. Therefore, the strong predictive 
value of AAC level for cardiovascular events provides influential simultaneous 
information to practitioner in order to get an estimation of cardiovascular risk in 
individuals referred for osteoporosis screening by DEXA. Moreover, while there 
is a hypothesis that body composition analysis and detection of AAC will both 
improve the utility of DEXA to predict cardiovascular disease outcomes, further 
research is required to test this. 
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Thus, due to little radiation exposure in DEXA imaging systems (less than 0.01 mSv 
vs. 2 mSv in lateral spine radiographs [19,22]), and efficiency of DEXA in detecting 
bone density, vertebral fracture, as well as abdominal aortic calcification, this 
method seems to be an appropriate tool in patients referred for osteoporosis 
detection for additional evaluation of cardiovascular risk. 
In a previous study, Schousboe et al. compared AAC in 369 cases of women with 
a mean age of 80 years compared with 363 controls [23]. They selected patients 
with stroke or myocardial infarction. There are several differences between 
this previous study and our study. Our study did not focus on elderly women 
but also included younger patients (mean age 68.5 yrs). More importantly, 
our study comprised 46% male population, and to our knowledge is the first 
study on cardiovascular predictive value of AAS detected by VFA in both sexes. 
Furthermore, all cardiovascular events, including TIA and cardiovascular death 
were evaluated. Finally, patients in that study were selected in a different way. 
They selected patients with stroke or Ml, whereas we prospectively included, all 
patients with a positive AAC result. The results however are comparable showing 
a strong predictive value of AAC. 
There were limitations in our study. This study represents retrospective data. Our 
population consists only of patients referred for VFA or osteoporosis. Data should 
be interpreted cautiously when dealing with other patient groups. Patients were 
screened for VFA and osteoporosis and laboratory data relevant for cardiovascular 
risk (e.g. LDL and HDL serum levels) were not available for all subjects. Moreover, 
further relevant variables such as blood pressure, medications, and condition 
of blood pressure control in hypertensive subjects were lacking in our study. 
Further studies for other ethnic groups, applying cardiovascular risk prediction 
systems, and designing cohorts with younger groups might be needed to obtain 
a better understanding of the predictive value of AAC measurements. Moreover, 
investigations comprising more subjects and longer follow-up period are thus 
needed. Although, some other studies [5, 11 ,23] showed a higher percentage AAC 
in their population than the 6% found in our study. However, our study comprised 
a younger population (52.8 vs. 60.7 [11 ], 69 [SJ, 80 [23] years) and patients without 
increased risk of cardiovascular disorders, which explains partly the lower 
detection rate for AAC. 
In conclusion, AAC assessed by VFA can predict non-fatal or fatal cardiovascular 
events among elderly men and women. This finding is independent of 
conventional risk factors for cardiovascular disease. The routine use of DEXA and 
VFA for osteoporosis and vertebral fracture screening contributes to a one-stop­
shop session with low costs, low radiation burden and a fast accessible way of 
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risk stratifying for cardiovascular events. Prospective large cohort studies with 
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Chapter 1 -This dissertation starts with a review on molecular imaging of 
cardiovascular diseases. An overview of current application of micro single 
photon emission tomography (microSPECT)/CT and micro positron emission 
tomography (microPET) in preclinical cardiovascular research was reviewed. In 
addition, prospective of nuclear medicine imaging application in visualization, 
characterization, and measurement of pathobiological processes underlying 
diseases at molecular and cellular levels. 
Given the important role of angiogenesis in progression and destabilization of 
atherosclerotic disease, in Chapters 2 and 3, the feasibility of molecular imaging 
for targeting molecules involved in angiogenesis in atherosclerosis was assessed 
using two radiopharmaceuticals in excised CEA specimens. 
In Chapter 2 of this thesis we tested whether [89Zr]-bevacizumab allows 
visualization of human vascular endothelial growth factors (VEGFs) using 
microPET imaging system. Due to the central role of intra-plaque release of VEGF 
in formation of new vessels in atherosclerotic plaques, concentration of VEGF can 
be considered as an indirect indicator for assessment of plaque vulnerability. 
Radiolabeled bevacizumab, a humanized monoclonal antibody, that targets 
all VEGF-A isoforms and has been used to visualize and quantify VEGF levels, 
angiogenesis, and anti-VEGF therapeutic effects in xenograft tumor models. In 
our study we showed for the first time that [89Zr]-labeled bevacizumab exerts 
promising characteristics for molecular imaging of VEGF abundance in human 
atherosclerotic plaques. In this study specific, heterogeneous, size-independent 
accumulation of [89Zr]-bevacizumab was shown in CEA specimens using ex vivo 
microPET imaging. 
Another molecule involved in process of angiogenesis is avrn integrin, a cell 
surface receptor, which facilitates angiogenesis by mediating migration of 
endothelial cells and their binding to extracellular matrix. In Chapter 3, feasibility 
of [ 1 8F]-RGD-K5 microPET imaging in visualization of av�B integrin was studied. 
In previous studies radiolabeled tripeptide sequence arginine-glycine-aspartate 
(RGD), which has a high affinity to av�3 integrin, showed promising characteristics 
as molecular imaging probe for detection of av�3 integrin expression in various 
models of tumors. In Chapter 3 we showed feasibility of ex vivo imaging of 
human CEA specimens with a recently developed RGD-containing [ 1 8F]-labeled 
compound, produced by click chemistry methods. 
In this study specificity and heterogeneity of [1 8F]-RGD-K5 accumulation in 
CEA specimens were shown and segmental accumulation levels of the tracer 
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was significantly correlated to immunohistochemistry results of av�3 integrin 
(p = 0.58, p = 0.038) and endothelial cells (p = 0.67, P < 0.002) in corresponding 
segments. These results showed the potential of RGD imaging in detection and 
quantification of av�3 integrin and new vessel density in human atherosclerotic 
plaque, and therefore the potentials of molecular imaging probes for depiction of 
processes underlying plaque vulnerability. 
In addition to its application in diagnosis, prognosis, and understanding of 
pathobiological features of diseases, molecular imaging offers a tool to visualize 
the effects of therapeutic interventions in vivo. In Chapter 4, the effects of 
minocycline (a second generation tetracycline) in reduction of apoptosis-necrosis 
spectrum was monitored by using [99mTc]-Annexin AS (AAS) micro SPECT and 
[111 ln]-labeled 4-(N-(s-glutathionylacetyl) amino) phenylarsenoide (GSAO) in 
small animal models of myocardial ischemia/reperfusion (1/R) injury. 
Binding affinity of AAS to phosphatidyl serine expression, which is translocated 
during apoptosis and cell membrane impermeability to GSAO (an intracellular 
molecules-avid agent) make AAS and GSAO promising radiotracer for imaging 
apoptosis and necrosis, respectively. 
TUNEL staining confirmed that minocycline treatment reduces the extent of 
myocardial damage in I/R injury. In vivo microSPECT and ex vivo gamma-counting 
showed a significant lower GSAO uptake in myocardial area at risk of minocycline­
treated animals when compared with vehicle-treated animals. Ex vivo imaging 
results of excised hearts showed significant lower AAS uptake in minocycline­
treated animals compared with untreated animals. 
In Chapter 5 the independent association between abdominal aortic calcification 
(AAC) detected by dual energy X-ray absorptiometry (DEXA) and myocardial 
infarction (Ml), stroke, and transient ischemic attack was demonstrated. In this 
study VFA images of 2500 patients were evaluated, detected and scored for AAC 
and a random AAC-negative age- and sex-adjusted control group was selected. 
Baseline cardiovascular risk factors and later incidence of Ml, stroke, or transient 
ischemic attacks were checked and a design based Cox regression analysis was 
used to examine the prognostic value of AAC for cardiovascular outcomes. 
Proportion of cardiovascular incidence in control, low-AAC, and high-AAC groups 
were 1.5%, 6.7%, and 11.9%, respectively. Multi-variable adjusted analysis showed 
a significant higher risk of cardiovascular incidents associated with presence and 




Despite considera ble advance in  therapeutic efforts and decl ine in death rates 
in the last decade, cardiovascular diseases remain the leading cause of death 
and morbidity worldwide. This is due to increased survival of patients with 
atherosclerosis, aging popu lation, obesity epidemic, the fact that sudden cardiac 
death is the first presentation of coronary heart d isease in 50% of men and 64% 
of women, and i mportantly the fact that a considerable proportion of individuals 
at high risk for cardiovascular diseases remain unrecognized or undertreated [1  ] .  
Atherosclerosis is  a pathological process within  the arteria l  wa l l. It  is characterized 
with a decade-long thickening of arteria l wal l, cholesterol deposition, 
inflammatory cel l s  recruitment, necrotic core formation, a rterial wal l  remodeling, 
angiogenesis, ca lcification, and protein degradation .  Atherosclerotic disease 
becomes symptomatic only at the late stages of the d isease because of l uminal 
narrowing or atherothrombosis at the site of plaque rupture. Conventional 
methods for assessment of atherosclerosis a re based on luminal  narrowing 
assessment (using angiography) or eva luation of downstream b lood supply by 
the artery (using perfusion imaging) [2] . 
Retrospective studies have shown that most hard events associated with 
atherosclerosis ( including myocardial  infarction, u nstable angina pectoris, and 
stroke) a re caused by atherosclerotic plaques that are angiographica l ly mi ld 
( <50% of lumen loss), and atherothrombosis as resu lt of plaque rupture is the 
cause of a s ign ificant decrease in blood supply a nd downstream compl ications 
[3, 4]. As such, it is of high cl inica l importance to differentiate the lesions that 
progress to rupture and cause myocardia l  infarction or stroke. This can provide 
cl inicians with valuable diagnostic tools to better risk stratify individuals at higher 
risk for future card iovascular event. Molecu lar imaging offers the potentia l for 
targeting molecular  and cel lu lar  processes underlying pathobiology of diseases. 
In addition, it can be used for in vivo monitoring of the effects of therapeutic 
interventions targeting these processes [5, 6] . 
Angiogenesis Imaging 
Althoug h the trad itional definition of vulnerable atherosclerotic plaque was 
based on inflammation and th in fibrous cap, more recently the role of intra-plaque 
hemorrhage as a resu ltofformation offragi le new vessels in process ofang iogenesis 
has gained interest [7] . Angiogenesis is no longer considered as a bystander in the 
process of atherosclerotic plaque progression and vulnerabi l ity, but its ro le in l ipid 
deposition, exacerbating inflammatory process, and intra-plaque hemorrhage 
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makes it a significant player in destabilization of atherosclerotic plaque. As such, 
targeting upstream processes preceding intra-plaque hemorrhage with molecular 
imaging would provide valuable information for early detection of vulnerable 
atherosclerotic plaques and offers the opportunity to track treatments that target 
angiogenesis in atherosclerotic lesions. 
Given the role of VEGF and av�3 integrin in the process of angiogenesis, these 
molecules can provide appropriate targets for molecular imaging of angiogenesis. 
We showed feasibility of targeted imaging of VEGF and av�3 integrin with 
radiolabeled humanized monoclonal anti-VEGF antibody (bevacizumab) and 
RGD, respectively. 
Although [ 1 8F]-FDG PET imaging has been proposed for detection of macrophage 
content and vulnerability of atherosclerotic plaques [8]; this method lacks 
specificity and a more specific tracer that can target the processes involved in 
plaque vulnerability would benefit researchers and clinicians. Due to the interplay 
between inflammation and angiogenesis in atherosclerosis, angiogenesis 
imaging can provide indirect information on inflammation in plaques. In, 
Chapter 2, we showed that VEGF staining in slides of atherosclerotic plaque co­
localizes with regions with high intensity for CD68 staining (as a surrogate marker 
for macrophages), suggesting the possible role for VEGF-targeted imaging 
for visualizing both VEGF abundance (directly) and macrophage infiltration 
(indirectly). This study suggests VEGF as an interesting potential target for 
visualization of pathobiological processes involved in development and (un) 
stability of atherosclerotic plaques. 
Cell Death Imaging 
Although reperfusion therapy is the first line management strategy for the patients 
manifesting acute Ml, after reperfusion a subset of cardiomyocytes suffer from 
oxidative reperfusion injury and is lost due to a poptotic and secondary necrotic eel I 
death. The potential of molecular imaging to evaluate effects of cardioprotective 
drugs (namely minocycline) with AAS and GSAO, as shown in Chapter 4 bears 
a promise. Cell death imaging provides researchers a tool for longitudinally 
investigating the effects of interventions aiming to reduce apoptotic and necrotic 
cell death and to assess long-term implication of myocardial cell death in heart 
function. 
Calcification Imaging 
Due to its systemic nature, atherosclerotic disease affects all arteries in the body. 
AAC as an indicator of atherosclerosis in abdominal aorta can be detected by 
lumbar x-ray and CT and is associated with high burden of atherosclerosis in other 
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vascular beds. Calcification detected by CT has been proposed as a valuable tool for 
screening individuals with intermediate risk for atherosclerosis. Interestingly, AAC 
can be detected and scored by VFA images using DEXA with a good agreement 
with gold standard lumbar x-ray. 
The independent strong predictive role of calcification detected by VFA, as shown 
in Chapter 5, makes VFA images a unique tool for opportunistic screening of 
individuals for atherosclerotic disease. The fact that bone mineral densitometry 
with DEXA is recommended in all women older than 65 years old [9] and VFA with 
DEXA takes an additional 10 seconds and imposes minimal radiation exposure 
(less than 0.01 mSv [1 0]) suggests DEXA imaging as a one-stop-shop-session 
for assessment of bone mineral density, vertebral fractures, and atherosclerosis 
burden. 
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Part 3 
Future Perspectives 
The purpose of this dissertation was to develop and validate molecular imaging 
methods for visualization and measurement of molecular and cellular targets 
involved in atherosclerotic diseases in different vascular beds and various models 
of the disease. Potentials of cardiovascular molecular imaging were investigated 
in animal models of disease, ex vivo human carotid endarterectomy (CEA) 
specimens, and abdominal aorta in individuals underwent vertebral fracture 
assessment (VFA). 
Plaque Vulnerability 
We showed correlations between bevacizumab and RGD-KS binding in 
atherosclerotic plaques and immunohistochemistry results of VEGF staining and 
integrin staining on sections of 4 mm-wide segments of atherosclerotic plaques. 
However, tissue accumulation of bevacizumab- and RGD-KS-based tracers needs 
to be correlated with protein levels and gene expression of target molecules to 
provide a better understanding of specificity and sensitivity of probes. Moreover, 
the ex vivo results of angiogenesis imaging studies need to be confirmed in vivo. 
Given the concept of the vulnerable plaque is defined retrospectively by post­
mortem evaluation of culprit plaques in patients with hard cardiovascular events, 
efforts on molecular imaging of vulnerable plaques in human involves difficult 
research design and implementation. On the other hand, small animal models of 
atherosclerotic plaque do not accurately mimic pathophysiology of vulnerable 
plaque. Development and validation of rodent models of atherosclerotic which 
better represent the underlying cascade of events that leads to plaque rupture 
would facilitate investigation of molecular imaging probes in detection of 
vulnerable plaques. Immune-deficient mice transplanted with human coronary 
artery can provide a potential animal model for imaging vulnerable atherosclerotic 
plaque in vivo. 
Molecular imaging research on vulnerable atherosclerotic plaque requires a better 
understanding of the overlapping and interactive pathways that play role in plaque 
vulnerability. Inflammation, angiogenesis, and matrix degradation contribute to 
destabilization of atherosclerotic plaques, however it is too simplistic to point at 
a single process as the main factor causing plaque vulnerability. As such, an ideal 
study for validating a novel probe for molecular imaging of vulnerable plaques 
should address not only the link between probe uptake and levels of direct 
target, but also the correlation between the probe uptake and other key players 
of plaque vulnerability. Moreover, clinical implications and predictive value of 
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molecular imaging probes need to be addressed in clinical studies to determine 
which pathophysiological process should be targeted for molecular imaging for 
prediction of atherosclerotic plaque complications. 
Cell Death 
Promising molecular imaging results on the effects of minocycline on myocardial 
apoptosis-necrosis spectrum in small animal models of 1/R injury, provide the 
evidence for further studies to investigate the long-term effects of minocycline 
(and other cell death inhibitory therapeutic interventions) on 1/R injury in small 
animal models. The possible effects of minocycline on myocardial remodeling, 
ejection fraction and heart failure can be monitored using small animal ultrasound 
and molecular imaging techniques to target cell death, matrix degradation, and 
fibrosis. 
Calcification 
In order to draw a conclusion on value of AAC detected by DEXA VFA, future 
large-scale prospective studies should be designed comprising subjects similar 
to general population and including relevant cardiovascular risk factors to 
investigate predictive value of VFA detected AAS in long-term. Also it is not clear 
how should the outcome of AAC-positive patients be altered, for example with 
risk modification or therapeutic intervention, which needs to be addressed in 
further studies. 
Calcification in a plaque is a result of both active and passive mineralization of a 
plaque. Passive calcium deposition occurs in the areas of foam cell necrosis and 
tissue degradation whereas; active calcification is a mechanism analogous to 
bone formation. X-ray-based imaging modalities can detect plaque extent and 
chronicity of calcified atherosclerotic plaques. However, combining the static 
information on existing calcification with visualization of ongoing progress of 
calcification within atherosclerotic plaques can provide information on past, 
present and future of atherosclerotic plaque in individuals. As such PET/CT 
imaging with 
[18F]-NaF, which can depict areas with continuing calcification can distinguish 
stable calcified atherosclerotic plaques from unstable active plaques. 
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Conclusions: 
In conclusion, we demonstrated promising imaging targets in preclinical as well as 
ex vivo studies for the evaluation iof atherosclerotic disease This potentially helps 
to advance the understanding of cardiovascular disease, design novel targeted 
imaging methods for better risk stratification of patients with atherosclerotic 
disease, and speed the drug discovery efforts that target disease progression. 
Further studies on the association of molecular and biological feature of 
cardiovascular system with accumulation of probes, comparative head-to-head 
analysis of targets, and improvement in imaging technology would enable us 
to design appropriate probes for imaging trace amounts of relevant biomarkers 
involved in atherosclerotic disease. Availability of a non- invasive, sensitive, and 
specific molecular imaging technique would provide clinicians incremental value 
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Samenvatting 
Hoofdstuk 1-Dit proefschrift begint met een overzichtsartikel over moleculaire 
beeldvorming in cardiovasculaire ziekten. Hierin wordt een overzicht van de 
huidige toepassingen van micro single photon emissie tomografie/ (SPECT/) 
CT en micro positron emissie tomografie (PET) in preklinisch cardiovasculair 
onderzoek weergegeven. Daarnaast worden de toekomstige mogelijkheden van 
het visualiseren, karakteriseren en meten van pathobiologische processen op 
moleculair en cellulair niveau die ten grondslag liggen aan de betreffende ziekte 
beschreven. 
Vanwege de belangrijke rol van vaatnieuwvorming (angiogenese) met betrekking 
tot de progressie en destabilisatie van atherosclerose (slagaderverkalking), 
wordt in Hoofdstuk 2 en 3 de haalbaarheid van moleculaire beeldvorming 
bij angiogenese onderzocht. Hierbij zijn twee typen radiofarmaca toegepast 
om angiogenese af te beelden in atherosclerotische plaques. Het gaat hier om 
stukjes halsslagader (arteria carotis) uit patienten. De stukjes zijn verwijderd om 
de vernauwing ten gevolge van atherosclerose te behandelen en om hiermee 
verdere schade bij de patienten te voorkomen. 
In Hoofdstuk 2 van dit proefschrift hebben we de mogelijkheid van [89Zr]­
bevacizumab geevalueerd voor het visualiseren van humane vascular endothelial 
growth factors (VEGFs). Hiervoor hebben we gebruik gemaakt van microPET 
beeldvorming. 
Radioactief gelabelde bevacizumab is een gehumaniseerd monocolonaal 
antilichaam dat aan alle VEGF-A isovormen bindt en reeds is gebruikt voor het 
afbeelden en kwantificeren van de aanwezigheid van VEGF & angiogenese en 
ook de effecten van anti-VEGF therapie in xenograft tumor diermodellen. Met 
onze studie werd voor het eerst aangetoond dat [89Zr]-labeled bevacizumab 
veelbelovende eigenschappen heeft voor het afbeelden van VEGF in humane 
atherosclerose plaques. We beschrijven en kwantificeren specifieke, heterogene 
accumulatie van [89Zr]-gelabelde bevacizumab in verwijderde atherosclerose 
plaques van de arteria carotis met behulp van microPET beeldvorming. 
Een ander molecuul dat een rol speelt in angiogenese is avfB integrine, een 
receptor op de eel membraan. av�3 integrine bewerkstelligt de migratie van 
endotheel cellen en integrine binding aan de extracellulaire matrix en speelt 
daarmee een belangrijke rol in angiogenese. In Hoofdstuk 3 is de mogelijkheid 
van [1 8FJ-RGD-K5 microPET beeldvorming voor het visualiseren van av�3 
integrine onderzocht. Eerdere onderzoeken in verschillende tumor modellen 
hebben laten zien dat de radioactief gelabelde tripeptide sequence arginine­
glycine-aspartate (RGD), dat goede bindingseigenschappen voor av�3 integrine 
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heeft, veelbelovende eigenschappen bezit als een diagnosticum met behulp 
van moleculaire beeldvorming van av�3 integrine expressie. In Hoofdstuk 3 
beschrijven wij verder de mogelijkheid van ex vivo beeldvorming van humane 
atherosclerotische plaques van de arteria carotis met [18F]-RGD-K5 dat met 
behulp van click-chemie methodiek is geproduceerd. 
In dit onderzoek werd specifieke en heterogene accumulatie van [18F]-RGD-KS in 
atherosclerose plaques aangetoond. Daarnaast werd een significante correlatie 
aangetoond tussen de accumulatie van de tracer in plaque segmenten en de 
aanwezigheid van av�3 integrine (p = 0.58, p = 0.038) en endotheel cellen (p 
= 0.67, P < 0.002) in de betreffende segmenten. Deze resultaten wijzen op de 
mogelijkheid van RGD beeldvorming voor de detectie en kwantificatie van av�3 
integrin expressieen de mate van vaatnieuwvorming in humaneatherosclerotische 
plaques. Dit benadrukt de waarde van moleculaire beeldvorming met behulp van 
specifieke tracers voor het in beeld brengen van processen die ten grondslag 
liggen aan de instabiele atherosclerotische plaques. 
Naast de toepassingen in de diagnostiek is dit onderzoek inzichtgevend voor beter 
begrip van de pathobiologische kenmerken van ziekte. Tenslotte kan moleculaire 
beeldvorming een instrument zijn voor het in vivo visualiseren van de effecten 
van therapeutische interventies. In Hoofdstuk 4 is de effectiviteit van minocycline 
(een tweede generatie tetracycline) voor het verminderen van het apoptose 
(geprogrammeerde celdood) en necrose in beeld gebracht met behulp van de 
tracers [99mTc]-Annexine AS micro SPECT en [ 1 11 ln]-4-(N-(s-glutathionylacetyl) 
amino) phenylarsenoide (GSAO). Het onderzoek werd uitgevoerd in diermodellen 
waarin het hartinfarct werd nagebootst. In de proefdieren ontstaat hierbij 
ischemie/reperfusie (1/R) schade. 
Het eiwit [99mTc]-Annexin AS bindt aan phosphatidyl serine, dat tijdens apoptose 
naar de buitenste membraan van cellen wordt verplaatst, en is daarmee een 
veelbelovend radioactief diagnosticum voor de beeldvorming van apoptose. 
GSAO bindt aan intracellulaire moleculen maar is wel membraan-impermeabel. 
Daarom is GSAO een veelbelovend radiofarmacon voor het in beeld brengen 
van necrose. Kenmerk van necrotische cellen is namelijk dat de celmembraan 
doorlaatbaar is geworden. Dit is niet het geval bij apoptotische cellen, die 
eveneens stervende zijn, maar waar de celmembraan nog intact is. 
TUNEL kleuring liet zien dat minocycline de mate van 1/R schade aan het 
hart vermindert. Daarnaast liet in vivo microSPECT beeldvorming en ex vivo 
radioactiviteitsmeting met behulp van gamma-counting een significant lagere 
accumulatie van GSAO zien in het infarctgebied van de harten van minocycline­
behandelde dieren in vergelijking met de placebo-behandelde dieren. Tot slot liet 
ex vivo beeldvorming een significant lagere accumulatie van [99mTc]-Annexine 
AS in harten van minocyline-behandelde dieren zien vergeleken met placebo­
behandelde dieren. 
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In Hoofdstuk 5 wordt een beschrijving gegeven van de onafhankelijke relatie 
tussen door dual energy X-ray absorptiometry (DEXA) gemeten abdominale 
aorta calcificatie (AAC) en cardiovasculaire incidenten, zoals myocard infarct (Ml), 
cerebrovasculaire accident (CVA), transient ischemic attack (TIA). In dit onderzoek 
zijn de laterale DEXA VFA (vertebral fracture assessment) beelden van 2500 
patienten geevalueerd, waarbij de aanwezigheid van AAC werd gedetecteerd 
en visueel gescoord. Ook werd een leeftijds- en geslacht gecorrigeerde controle 
groep gerandomiseerd en geselecteerd. Baseline cardiovasculaire risico's en het 
optreden van Mis, CVAs en TIAs werden genoteerd. Met behulp van Cox regressie 
werd de prognostische waarde van AAC voor cardiovasculaire uitkomsten 
geevalueerd. De proporties van cardiovasculaire incidentie in controle, lage-AAC 
score en hoge AAC score groepen waren respectievelijk 1.5%, 6.7%, en 1 1.9%. 
Een multi-variabele-gecorrigeerde analyse liet een significant verband zien 
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